

Bibliografia

- Abadir PM, Carey RM, Siragy HM et al (2003) Angiotensin AT₂ receptors directly stimulate renal nitric oxide in bradykinin B₂ receptor-null mice. *Hypertension* 42:600-604
- Abadir PM, Periasamy A, Carey RM et al (2006) Angiotensin II type 2 receptor-bradykinin B₂ receptor functional heterodimerization. *Hypertension* 48:316-322
- AbdAlla S, Lother H, Quitterer U (2000) AT₁-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. *Nature* 407:44-48
- AbdAlla S, Lother H, Massiery AE et al (2001a) Increased AT₁ receptor heterodimers in preeclampsia mediates enhanced angiotensin II responsiveness. *Nature Med* 7:1003-1009
- AbdAlla S, Lother H, Abdel-Tawab AM et al (2001b) The angiotensin II AT₂ receptor is an AT₁ receptor antagonist. *Biol Chem* 276:39721-39726
- AbdAlla S, Lother H, Langer A et al (2004) Factor XIIIa transglutaminase crosslinks AT₁ receptor dimers of monocytes at the onset of atherosclerosis. *Cell* 119:343-354
- Abdel-Rahman AM, Burrell LM, Johnston CI (1993) Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin and aldosterone. *J Hypertens* 11(S3):S23-26
- Abdel-Rahman AM, Siragy HM (2004) AT₂ Renin Aspects. In: Unger T, Scholkens BA (eds). *Angiotensin*, vol. I, Springer-Verlag Berlin Heidelberg, pp 423-447
- Achard J-M, Fournier A, Mazouz H et al (2001) Protection against ischemia: a physiological function of the renin-angiotensin system. *Biochem Pharmacol* 62:261-271
- Akishita M, Ito M, Lethonen JY et al (1999) Expression of the AT₂ receptor developmentally programs extracellular signal-regulated kinase activity and influences fetal vascular growth. *J Clin Invest* 103:63-71
- Akishita M, Horiuchi M, Yamada H et al (2000) Inflammation influences vascular remodeling through AT₂ expression and signaling. *Physiol Genomics* 2:13-20
- Akishita M, Nagai K, Xi H et al (2005) Renin-Angiotensin System modulates oxidative stress-induced endothelial cell apoptosis in rats. *Hypertension* 45:1188-1193
- Albiston AL, McDowall SG, Matsopoulos D et al (2001) Evidence that the angiotensin IV (AT₄) receptor is the enzyme-regulated aminopeptidase. *J Biol Chem* 276:48623-48626
- Ali MS, Schieffer B, Delafontaine P et al (1997) Angiotensin II stimulates tyrosine phosphorylation and activation of insulin receptor substrate 1 and protein-tyrosine phosphatase 1D in vascular smooth muscle cells. *J Biol Chem* 272:12373-12379
- Allen AM, Mac Gregor DP, McKinley MJ et al (1999) Angiotensin II receptors in human brain. *Regul Pept* 79:1-7
- Allen AM, Zhuo J, Mendelsohn FAO (2000) Localization and function of Angiotensin AT₁ receptors. *Am J Hypertens* 13:31S-38S
- Ambuhl P, Felix D, Imboden H et al (1992) Effects of angiotensin analogues and angiotensin receptor antagonists on paraventricular neurones. *Regul Pept* 38:111-120
- Ameisen JC (1999) *La Sculpture du Vivant. Le Suicide cellulaire ou la Mort créatrice*. Editions du Seuil, Paris
- Anborgh PH, Seachrist JL, Dale LB et al (2000) Receptor/ β -arrestin complex formation and the differential trafficking and resensitization of β ₂-adrenergic and angiotensin II type 1A receptors. *Mol Endocrinol* 14:2040-2053

- Ando H, Zhou J, Macova M et al (2004) Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. *Stroke* 35:1726-1731
- Ardaillou R, Chansel D (1998) Angiotensin II fragments. Effects and pathways of synthesis. In: Ulfedahl HR, Aurell M (eds) *Renin-Angiotensin*. Portland Press London, pp 47-75
- Argenziano L, Trimarco B et al (1999) Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double blind, multicentre study. *Eprosartan Multinational Study Group. Curr Med Res Opin* 15:9-14
- Asano K, Dutcher DL, Port JD et al (1997) Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. *Circulation* 95:1193-1200
- Aurell M (1998) Robert Tigerstedt - Scientist, Teacher and Critic. In: Ulfedahl HR, Aurell M (eds) *Renin-Angiotensin*. Portland Press London, pp 1-12
- Azizi M, Ménard J (2004) Combined Blockade of the Renin Angiotensin System with ACE Inhibitors and AT1 Receptor Antagonists. In: Unger T, Scholkens BA (eds) *Angiotensin*, Springer-Verlag Berlin Heidelberg, vol II, pp 485-516
- Balmforth AJ, Lee AJ, Bajaj BPS et al (1995) Functional domains of the C-terminus of the rat angiotensin AT1A receptor. *Eur J Pharmacol* 29:135-141
- Balmforth AJ, Shepherd FH, Warburton B et al (1997) Evidence of an important and direct role for protein-kinase C in agonist-induced phosphorylation leading to desensitization of the angiotensin AT1A receptor. *Br J Pharmacol* 122:1469-1477
- Balt JC, Mathy M-J, Nap A et al (2001) Effect of the AT1 receptor antagonists Losartan, Irbesartan and Telmisartan on angiotensin II -induced facilitation of sympathetic neurotransmission in the rat mesenteric artery. *J Cardiovasc Pharmacol* 38:141-148
- Balt JC, Pfaffendorf M (2004) Sympathetic Interactions of AT1 Receptors. In: Unger T, Scholkens BA (eds) *Angiotensin*. Springer-Verlag Berlin Heidelberg, vol I, pp 350-372
- Baracho NC, Simoes-e-Silva A, Khosla MC et al (1998) Effect of selective angiotensin antagonists on the antidiuresis produced by angiotensin (1-7) in water-loaded rats. *Braz J Med Biol Res* 31:1221-1227
- Barber MN, Sampey DB, Widdop RE (1999) AT2 receptor stimulation enhances antihypertensive effect of AT1 receptor antagonist in hypertensive rats. *Hypertension* 34:1112-1116
- Barki-Harrington L (2004) Oligomerization of angiotensin receptors: novel aspects in disease and drug therapy. *J Renin-Angiotensin-Aldosterone System* 5:49-52
- Batenburg W, Garrelts IM, Bernasconi C et al (2004) Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. *Circulation* 109:2296-2301
- Bayorth MA, Eatman D, Walton M et al (2002) A-799 attenuates angiotensin (1-7) depressor response in salt-induced hypertensive rats. *Peptides* 23:57-64
- Bedecs K, Elbaz N, Sutren M et al (1997) Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. *Biochem J* 325:449-454
- Belz GG, Breithaupt-Grogler K, Butzer R et al (2000) The pharmacological potency of various AT1 antagonists assessed by Schild regression technique in man. *J Renin-Angiotensin-Aldosterone System* 1:336-341
- Bergsma DJ, Ellis C, Nutulaganti PR et al (1993) Isolation and expression of a novel angiotensin receptor from *Xenopus laevis* heart. *Mol Pharmacol* 44:277-284
- Berk BC (1999) Angiotensin II signal transduction in vascular smooth muscle: Pathways activated by specific tyrosine kinase. *J Am Soc Nephrol* 10(S 11):S62-S68
- Berlowitz MS, Latif F, Hankins SR et al (2001) Dose-dependent blockade of angiotensin II type 1 receptor with Losartan in normal volunteers. *J Cardiovasc Pharmacol* 37:692-696
- Berne RM, Levy MN (2000) *Principles of Physiology*. Mosby Inc, St. Louis
- Bernier SG, Servant G, Boudreau M et al (1995) Characterization of a binding site for angiotensin IV on bovine aortic endothelial cells. *Eur J Pharmacol* 291:191-200
- Berry C, Touyz R, Domiczak RC et al (2001) Angiotensin receptors: signaling, vascular pathophysiology and interactions with ceramide. *Am J Physiol* 281:H2337-H2365

- Blankley CJ, Hodges JC, Klutchko SR et al (1991) Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT₂ type. *J Med Chem* 34:3248-3260
- Blum RA, Kazierad DJ, Tenero DM (1999) A review of eprosartan: pharmacokinetic and pharmacodynamic drug interaction studies. *Pharmacotherapy* 19(4 Pt 2):79S-85S
- Blume A, Kaschina E, Unger T (2001) Angiotensin II type 2 receptors: signaling and pathophysiological role. *Curr Opin Nephrol Hypertens* 10:239-246
- Bockaert J, Marin P, Dumuis A et al (2003) The "magic tail" of G protein-coupled receptors: an anchorage for functional protein networks. *FEBS Lett* 546:65-72
- Booz GW, Conrad KM, Hess AL et al (1992) Angiotensin binding sites on hepatocyte nuclei. *Endocrinology* 130:3641-3649
- Booz GW, Baker KM (1996) Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. *Hypertension* 28(4):635-640
- Bottari SP, Taylor V, King IN et al (1991) Angiotensin II AT₂ receptors do not interact with guanine nucleotide binding proteins. *Eur J Pharmacol* 207:157-163
- Bovec KC, Wong PC, Timmermans PBMW et al (1991) Effects of nonpeptide angiotensin II receptor antagonist DuP753 on blood pressure and renal functions in spontaneously hypertensive dog. *Am J Hypertens* 4:327S-333S
- Brede M, Roell W, Ritter O et al (2003) Cardiac hypertrophy is associated with decreased eNOS expression in angiotensin AT₂ receptor-deficient mice. *Hypertension* 42:1177-1182
- Brede M, Hein L (2004) Knockout Models of the Renin-Angiotensin System. In: Unger T, Scholkens BA (eds) *Angiotensin*. Springer-Verlag Berlin Heidelberg, vol I, pp 207-227
- Brenner BM, Cooper ME, De Zeeuw D et al (2001) Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 345:861-869
- Britto RR, Santos RAS, Fagundes-Moura CR et al (1997) Role of angiotensin (1-7) in the modulation of baroreflex in renovascular hypertensive rats. *Hypertension* 30:549-556
- Brookman L, Rolan P, Benjamin I et al (1997) Pharmacokinetic of Valsartan in patients with liver disease. *Clin Pharmacol Ther* 62:272-278
- Brosnihan KB, Li P, Ferrario CM (1996) Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. *Hypertension* 27:523-528
- Brosnihan KB, Liomar Neves AA, Chappell MC (2005) Does the angiotensin-converting enzyme (ACE)/ACE2 balance contribute to the fate of angiotensin peptides in programmed hypertension? *Hypertension* 46:1097-1099
- Brunner H (1997) The new receptor antagonist Irbesartan: pharmacokinetic and pharmacodynamic considerations. *Am J Hypertens* 10:311S-317S
- Brunner H (2002) The new angiotensin II receptor antagonist olmesartan medoxomil: a concise overview. *J Hum Hypertens* 16:S13-S16
- Buisson B, Laflamme L, Bottari SP et al (1995) A G protein is involved in the angiotensin AT₂ receptor inhibition of the T-type calcium current in differentiated NG 108-15 cells. *J Biol Chem* 270:1670-1674
- Bullock GR, Steynert I, Bilbe G et al (2001) Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease. *Histochem Cell Biol* 115:117-124
- Bumpus FM, Catt KJ, Chiu AT et al (1991) Nomenclature of angiotensin receptors. *Hypertension* 17:720-721
- Bunemann M, Lee KB, Pals-Rylaarsdam R et al (1999) Desensitization of G-protein-coupled receptors in the cardiovascular system. *Ann Rev Physiol* 61:169-192
- Buoninconti R, Buoninconti R (2000) Il Sistema Renina-Angiotensina cerebrale ed il suo Ruolo nel Controllo della Pressione Arteriosa. Springer-Verlag Milano
- Buoninconti R (2005) Il Sistema Renina-Angiotensina Cerebrale: dati clinici e sperimentali. In: Borghi C (ed) *Sistema Renina-Angiotensina-Aldosterone e Rischio Cerebrovascolare*. Primula Multimedia, pp 38-50
- Burnier M, Brunner HR (2000) Angiotensin II receptor antagonists. *Lancet* 355:637-645

- Burnier M, Rutschmann B, Nussberger J et al (1993) Salt-dependent effects of angiotensin II antagonists in healthy subjects. *Hypertension* 22:339-347
- Burnier M, Brunner HR (1994) Angiotensin II receptor antagonists and the kidney. *Curr Opin Nephrol Hypertens* 3:537-545
- Burnier M, Waeber M, Brunner H (1995) Clinical pharmacology of the angiotensin II receptor antagonist Losartan potassium in healthy subjects. *J Hypertens* 13(S 1):S23-S28
- Burnier M, Roch-Ramel F, Brunner H (1996) Renal effects of angiotensin II receptor blockade in normotensive subjects. *Kidney Int* 46:1787-1790
- Camara AKS, Osborn J (2001) Central AT1 and AT2 receptors mediate chronic intracerebroventricular angiotensin II -induced drinking in rats fed high sodium chloride diet from weaning. *Acta Physiol Scand* 171:195-201
- Campbell DJ (2001) Bioactive Angiotensin Peptides other than Angiotensin II. In: Epstein M, Brunner H (eds) *Angiotensin Receptors Antagonists*. Hanley & Belfus Inc, pp 9-27
- Cao Z, Dean R, Wu L et al (1999) Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy. *Hypertension* 34:408-414
- Carey RM, Wang ZQ, Siragy HM (2000 a) Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. *Hypertension* 35(pt 2):155-163
- Carey RM, Jin X, Wang Z et al (2000b) Nitric oxide: a physiological mediator of the type 2 (AT2) angiotensin receptor. *Acta Physiol Scand* 168:65-71
- Carey RM, Howell NL, Jin XH et al (2001) Angiotensin Type 2 receptor-mediated hypotension in angiotensin type 1 receptor-blocked rats. *Hypertension* 38:1272-1277
- Carey RM (2004) Angiotensin type-1 receptor blockade increases ACE2 expression in the heart. *Hypertension* 43:943-944
- Carey RM (2005a) Update on the role of the AT2 receptor (circulation and hemodynamics). *Curr Opin Nephrol Hypertens* 14:67-71
- Carey RM (2005b) Cardiovascular and renal regulation by the angiotensin type 2 receptor: The AT2 receptor comes of age. *Hypertension* 45:840-844
- Carini DJ, Duncia JV, Aldrich PE et al (1991) Nonpeptide angiotensin II receptor antagonists: the discovery of a series of n-(biphenylmethyl) imidazoles as potent, orally-active antihypertensives. *J Med Chem* 34:2525-2547
- Caruso-Neves C, Lara SL, Rangel LB et al (2000) Angiotensin-(1-7) modulates the ouabain-insensitive Na⁺ -ATPase activity from bilateral membrane of the proximal tubule. *Biochim Biophys Acta* 1467:189-197
- Casini A (2000) Alcohol-induced fatty liver and inflammation: where do Kupffer cells act? *J Hepatol* 32:1026-1030
- Cazaubon C, Gougat J, Bouscet F et al (1993) Pharmacologic characterization of SR 47436: A new nonpeptide AT1 subtype angiotensin II receptor antagonist. *J Pharmacol Exp Ther* 265:826-834
- Cervenka L, Maly J, Karasova L et al (2001) Angiotensin II-induced hypertension in bradykinin B2 receptor knockout mice. *Hypertension* 37:967-973
- Cesari M, Rossi GP, Pessina AC (2002) Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases. *J Hypertens* 20:793-799
- Chai SY, Bastias MA, Clune EF et al (2000) Distribution of the angiotensin IV binding sites (AT(4) receptor) in the human forebrain, midbrain and pons as visualized by in vitro receptor autoradiography. *J Chem Neuroanat* 20:339-348
- Chai SY, Mendelsohn FAO, Lee J et al (2004) Angiotensin AT4 Receptor. In: Unger T, Scholkens BA (eds) *Angiotensin*. Springer-Verlag Berlin Heidelberg 2004, pp 519-538
- Chaki S, Inagami T (1992) Identification and characterization of a new binding site for angiotensin II in mouse neuroblastom Neuro-2A cells. *Biochem Biophys Res Commun* 182:388-394
- Chan DP, Sandok EK, Aarhus LL et al (1992) Renal specific effects of angiotensin II receptor antagonism in the anesthetized dog. *Am J Hypertens* 5(S2):354-360

- Chan YC, Leung PS (2006) AT1 receptor antagonism ameliorates acute pancreatitis-associated pulmonary injury. *Regul Pept* 134:46-53
- Chang RSL, Lotti VJ (1990) Two distinct angiotensin II receptor binding sites in adrenal revealed by new selective non peptide ligands. *Mol Pharmacol* 29:347-351
- Chappell MC, Pirro NT, Sykes A et al (1998) Metabolism of angiotensin-(1-7) by angiotensin converting enzyme. *Hypertension* 31:362-367
- Chappell MC, Bosch SM, Hansen RC et al (1994) Angiotensin II receptor subtype expression in the primate pancreas. *Am J Hypertens* 4:92A
- Chen X, Li W, Yoshida H et al (1997) Targeting deletion of angiotensin type 1B receptor gene in the mouse. *Am J Physiol* 272:F299-F304
- Chen S, Patel JM, Block ER (2000) Angiotensin IV-mediated pulmonary artery vasorelaxation is due to endothelial intracellular calcium release. *Am J Phys* 279:L849-L85
- Chen Y, Joaquim LF, Fara VM et al (2005) Cardiovascular autonomic control in mice lacking angiotensin AT1a receptors. *Am J Physiol* 288:R1071-R1077
- Chiu AT, McCall DE, Nguyen TT et al (1989) Discrimination of angiotensin receptor subtypes by dithiothreitol. *Eur J Pharmacol* 170:117-118
- Chiu AT, McCall DE, Price WAJ et al (1991) In vitro pharmacology of DuP753. *Am J Hypertens* 4:282S-287S
- Chiu AT, Smith RD, Timmermans (1994) Defining Angiotensin Receptors subtypes. In: Saavedra JM, Timmermans PBMWM (eds) *Angiotensin Receptors*. Plenum Press New York, pp 49-65
- Chiu AG, Krowiak EJ, Deeb ZE (2001) Angioedema associated with angiotensin II antagonists: challenging our knowledge of angioedema and its etiology. *Laryngoscope* 111:1729-1731
- Christen Y, Waeber B, Nussberger J et al (1991) Oral administration of DuP753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. *Circulation* 83:1333-1342
- Chung O, Kuhl H, Stoll M et al (1998) Physiological and pharmacological implications of AT1 versus AT2 receptors. *Kidney Int* 54:Suppl 67:95-103
- Cigola E, Kaistura J, Li B et al (1997) Angiotensin II activates programmed myocyte cell death in vitro. *Exp Cell Res* 231:363-371
- Clark MA, Tallant EA, Diz DI (2001) Angiotensin-(1-7) downregulates the angiotensin II type 1 receptor in vascular smooth cell. *Hypertension* 37:1141-1146
- Clark MA, Tommasi EN, Bosch SM et al (2003) Angiotensin-(1-7) reduces renal angiotensin II receptors through a cyclooxygenase-dependent pathway. *J Cardiovasc Pharmacol* 41:276-283
- Clermont A, Bursell S-E, Feener EP (2006) Role of angiotensin type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. *J Hypertens* 24 (S.1):S73-S80
- Coffman TM, Audoly LP, Oliverio M (2001) Gene targeting studies of angiotensin II type 1 (AT1) receptors. *J Renin-Angiotensin-Aldosterone Syst* 2 (SI):S 10-S15
- Cohn JN, Tognoni G for the Valsartan Heart Failure Trial Investigators (2001) A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. *N Engl J Med* 345:1667-1675
- Cohn JN (2003) Val-HeFT: changing the heart failure horizon. *Eur Heart J* 5(S. C):C25-C28
- Coleman JK, Krebs LT, Hamilton TA et al (1998) Autoradiographic identification of kidney angiotensin IV binding sites and angiotensin IV-induced renal cortical blood flow changes in rats. *Peptides* 34:269-277
- Collister JP, Hornfeldt BJ, Osborn JW (1996) Hypotensive response to Losartan in normal rats. Role of Ang II and Area Postrema. *Hypertension* 27(pt 2):598-606
- Collister JP, Osborn JW (1998) Area Postrema lesion attenuates the long-term hypotensive effects of Losartan in salt-repleted rats. *Am J Physiol* 274:R357-R366
- Collister JP, Soucheray SL, Osborn JW (2002) Chronic hypotensive effects of Losartan are not

- dependent on the actions of Angiotensin II at AT₂ receptors. *J Cardiovasc Pharmacol* 39:107-116
- Collister JP, Hendel MD (2003) Role of the subfornical organ in the chronic hypotensive response to Losartan in normal rats. *Hypertension* 41:576-582
- Conchon S, Monnot C, Teutsch B et al (1994) Internalization of the rat AT_{1A} and AT_{1B} receptors: Pharmacological and functional requirements. *FEBS Lett* 349:365-370
- Conchon S, Barrault MB, Misarey S et al (1997) The C-terminal third intracellular loop of the rat AT_{1A} angiotensin receptor plays a key role in G Protein coupling specificity and transduction of the mitogenic signal. *J Biol Chem* 272:25566-25572
- Conchon S, Clauser E (2004) AT₁ Receptor Molecular Aspects. In: Unger T, Scholkens BA (eds) *Angiotensin*. Springer-Verlag Berlin Heidelberg, vol 1, pp 269-295
- Conlin PR, Spence JD, Williams B et al (2000) Angiotensin antagonists for hypertension: are there differences in efficacy? *Am J Hypertens* 13:418-426
- Cook MD, Phillips MI, Cook VI et al (1993) Angiotensin II receptor subtypes on adrenal adenoma in primary hyperaldosteronism. *J Am Soc Nephrol* 4:111-116
- Cook CL, Weiser MC, Schwartz PE et al (1994) Developmentally timed expression of an embryonic growth phenotype in vascular smooth muscle cells. *Circulation Res* 74:189-196
- Correa FMA, de Oliveria AM, Viswanathan M et al (1994) Autoradiographic localization and characterization of angiotensin II receptor subtypes in rat thymus. *Peptides* 15:821-824
- Correa SAA, Zalcberg H, Han SW et al (2002) Aliphatic amino acids in helix VI of the AT₁ receptor play relevant role in agonist binding and activity. *Regul Pept* 106:33-38
- Costagliola C, Verdino M, Iaccarino G et al (1999) Losartan potassium oral administration decreases intraocular pressure in humans. A pilot study. *Clin Drug Invest* 17:329-332
- Cote F, Do T, Laflamme L et al (1999) Activation of the AT₂ receptors of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum. *J Biol Chem* 274:31686-31692
- Cox SL, Ben A, Story DF et al (1995) Evidence for the involvement of different receptor subtypes in the pre- and postjunctional actions of angiotensin II at rat sympathetic neuroeffector sites. *Br J Pharmacol* 114:1057-1063
- Crackower MA, Sarao R, Oudit GY et al (2002) Angiotensin-converting enzyme 2 is an essential regulator of heart function. *Nature* 417:822-828
- Criscione L, Bradley W, Buhlmayer P (1995) Valasartan: preclinical and clinical profile of an antihypertensive angiotensin II antagonist. *Cardiovasc Drug Rev* 13:230-250
- Crozier I, Ikram H, Awan N et al (1995) Losartan in heart failure. Hemodynamic effects and tolerability. Losartan hemodynamic study group. *Circulation* 91:691-697
- Cui T, Nakagami H, Iwai M et al (2000) ATRAP, novel AT₁ receptor associated protein, enhances internalization of AT₁ receptor and inhibits vascular smooth muscle cell growth. *Biochem Biophys Res Commun* 279:938-941
- Culman J, Blume A, Gohlke P et al (2002) The renin-angiotensin System in the brain: possible therapeutic implications of AT₁ receptor blockers. *J Hum Hypertens* 16:S64-S70
- Curnow KM (1996) Human type-1 angiotensin II (AT₁) receptor gene structure and function. *Clin Exp Pharmacol Physiol* 3:S67-S73
- Dahlof B, Devereux R, deFaire U et al (1997a) The Losartan Intervention for Endpoint Reduction (LIFE) in hypertension study. Rationale, design and methods. *Am J Hypertens* 10:705-713
- Dahlof B, Lindholm LH, Carney S et al (1997 b) Main results of the Losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. *J Hypertens* 15:1327-1335
- Dahlof B, Devereux RA, Kjeldsen SE et al ((2002a) Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against Atenolol. *Lancet* 359:995-1003
- Dahlof B, Zanchetti A, Diez J et al (2002b) Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in essential hypertensives with left ventricular hypertrophy. *J Hypertens* 20:1855-1864

- Dahlof B, Burke TA, Krobot K et al (2004) Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE). *J Hum Hypertens* 18:367-373
- Dai W-J, Funk A, Herdegen T et al (1999) Blockade of central angiotensin AT1 receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. *Stroke* 30:2391-2399
- Dale LB, Seachrist J, Babwah AV et al (2004) Regulation of angiotensin II type 1A receptor intracellular retention, degradation, and recycling by Rab5, Rab7 and Rab11 GTPases. *J Biol Chem* 279:13110-13118
- Dalmay F, Mazouz H, Allard J et al (2001) Non AT(1)-receptor-mediated protective effect of angiotensin against acute ischemic stroke in the gerbil. *J Renin-Angiotensin-Aldosterone Syst* 2:103-106
- D'Amore A, Black M Jane, Thomas WG (2005) The Angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize Angiotensin II type 1 receptor-mediated hypertrophy. *Hypertension* 46:1347-1354
- Danilczyk U, Eriksson U, Crackower MA (2003) A story of two ACEs. *J Mol Med* 81:227-234
- Danilczyk U, Eriksson U, Oudit GY et al (2004) Physiological roles of angiotensin-converting enzyme 2. *CMLS, Cell Mol Life Sci* 61:2714-2719
- Danser AHJ (2004) Renin-Angiotensin System: Plasma versus Tissues. In: Unger T, Scholkens BA (eds) *Angiotensin*, Springer-Verlag Berlin Heidelberg, vol.1, pp 129-147
- Dantas AVP, Sandberg K (2005) Regulation of ACE2 and Ang-(1-7) in the aorta: new insights into the renin-angiotensin System in the control of vascular function. *Am J Physiol* 289:H980-H981
- Daugherty A, Manning MW, Cassis LA (2001) Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. *Br J Pharmacol* 134:865-870
- Daviet L, Lethonen J, Tamura K et al (1999) Cloning and characterization of ATRAP, a novel protein that interacts with the angiotensin II type 1 receptor. *J Biol Chem* 274:17058-17062
- Daviet L, Lethonen J, Hayashida W et al (2001) Intracellular third loops in AT1 and AT2 receptors determine subtype specificity. *Life Sci* 69:509-516
- Davisson RL, Oliverio MI, Coffman TM et al (2000) Divergent functions of angiotensin II receptor isoforms in the brain. *J Clin Invest* 106:103-106
- de Blois D, Tea B-S, Dam T-V et al (1997) Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats. *Hypertension* 29(pt 2):340-349
- de Castro CH, dos Santos RAS, Ferreira AJ et al (2005) Evidence for a functional interaction of the Angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. *Hypertension* 46(pt 2):937-942
- de Gasparo M, Whitebread S, Bottari SP et al (1994 a) Heterogeneity of Angiotensin Receptor Subtypes. In: Timmermans PBMWM, We/xler RR (eds) *Medicinal Chemistry of the Renin-Angiotensin System*. Elsevier Amsterdam, pp 269-294
- de Gasparo M, Levens NR, Kamber B et al (1994b) The Angiotensin II AT2 Receptor Subtype. In: Saavedra JM, Timmermans PBMWM (eds) *Angiotensin Receptors*. Plenum Press New York London, pp 95-117
- de Gasparo M, Whitebread S, Kalenga MK et al (1994c) Downregulation of angiotensin II receptor subtype AT2 in human myometrium during pregnancy. *Regul Pept* 53:39-45
- de Gasparo M, Bottari S, Levens NR (1995a) Characteristics of Angiotensin II Receptors and their Role. In: Laragh JH, Brenner BM (eds) *Hypertension. Pathophysiology, Diagnosis and Management*. Raven Press, New York, pp 1695-1720
- de Gasparo M, Husain A, Alexander W et al (1995b) Proposed update of angiotensin receptors nomenclature. *Hypertension* 25:924-939
- de Gasparo M, Siragy HM (1999) The AT2 receptor: fact, fancy and fantasy. *Regul Pept* 81: 11-24

- de Gasparo M, Catt KJ, Inagami T et al (2000) International Union of Pharmacology. XXIII. The Angiotensin II Receptors. *Pharmacol Rev* 52:415-472
- de Gasparo M (2004) AT1 Receptor Antagonists: Pharmacology. In: Unger T, Scholkens BA (eds) *Angiotensin*. Springer-Verlag Berlin Heidelberg, vol 11, pp 417-451
- Degli EE, Sturani A, Di Martino M et al (2002) Long-term persistence with antihypertensive drugs in new patients. *J Hum Hypertens* 16:439-444
- de Godoy MAF, de Oliveira AM, Rattan S (2004) Angiotensin II-induced relaxation of aortic smooth muscle via desensitization of AT1 receptor, and activation of AT2 receptor associated with nitric-oxide synthase pathway. *J Pharmacol Exp Ther* 311:394-401
- Delorenzi A, Locatelli F, Romano A et al (1997) Angiotensin II (3-8) induces long-term improvement in the crab chasmagnatus. *Neurosci Lett* 226:143-146
- De Souza AM, Lopes AG, Pizzino CP et al (2004) Angiotensin II and Angiotensin-(1-7) inhibit the inner cortex Na^+ -ATPase activity through AT2 receptor. *Regul Pept* 120:167-175
- Devereux RB, Palmieri W, Liu JE et al (2002) (The LIFE Study) Progressive hypertrophy regression with sustained pressure reduction in hypertension. *J Hypertens* 20:1445-1450
- de Zeeuw D, Remuzzi G, Kirch W (1997) Pharmacokinetics of Candesartan cilexetil in patients with renal or hepatic impairment. *J Hum Hypertens* 11 (S 2):S37-S42
- Dickstein K, Kjekshus J (2002) Effects of Losartan and Captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. *Lancet* 360:752-760
- Diep QN, Li J-S, Schiffrin EL (1999) In vivo study of AT1 and AT2 angiotensin receptors in apoptosis in rat blood vessels. *Hypertension* 34:617-624
- Diep QN, El Mabrouk M, Yue P et al (2002) Effect of AT1 receptor blockade on cardiac apoptosis in angiotensin II-induced hypertension. *Am J Physiol* 282:H1635-H1641
- Diet F, Pratt RE, Berry GJ et al (1996) Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. *Circulation* 94:2756-2767
- Diez J, Panizo A, Hernandez M et al (1997) Cardiomyocyte apoptosis and cardiac angiotensin-converting enzyme in spontaneously hypertensive rats. *Hypertension* 30:1029-1034
- Dimmeler S, Ripman V, Weiland U et al (1997) Angiotensin II induces apoptosis of human endothelial cells: protective effects of nitric oxide. *Circ Res* 81:970-976
- Dinh DT, Frauman AG, Casley DJ et al (2001) Angiotensin AT4 receptors in the normal human prostate and benign prostatic hypertrophy. *Mol Cell Endocrinol* 184:187-192
- Dinh DT, Frauman AG, Johnston CI et al (2001) Angiotensin receptors: distribution, signaling and functions. *Clin Sci* 100:481-492
- Diz DI, Ferrario CM (1996) Angiotensin Receptor Heterogeneity in the Dorsal Medulla Oblongata as defined by Angiotensin-(1-7). In: Raizada MK, Phillips Mi, Summers C (eds) *Recent Advances in Cellular and Molecular Aspects of Angiotensin Receptors*. Plenum Press New York London, pp 225-235
- Diz DI, Westwood BM (2000) Deficiency of endogenous angiotensin-(1-7) in the nucleus tractus solitarius of (mREN2)27 transgenic rats may account for diminished baroreceptor reflex function. *Hypertension* 36:681
- Diz DI, Chappell MC, Tallant EA et al (2005) Angiotensin-(1-7). In: Oparil S, Weber MA (eds) *Hypertension*. Elsevier Saunders, pp 100-110
- Donoghue M, Hsieh F, Baronas E et al (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin 1 to angiotensin 1-9. *Circ Res* 87:E1-E9
- Douglas JG (1996) The curtain raises on the Renin-Angiotensin System: AT2 receptors are in the spotlight. *J Clin Invest* 97:1787
- Doulton TWR, He FJ, MacGregor GA (2005) Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. *Hypertension* 45:880-886
- Dubey RK, Jackson EK, Rupprecht HD et al (1997) Factors controlling growth and matrix

- production in vascular smooth muscle and glomerular cells. *Curr Opin Nephrol Hypertens* 6:88-105
- Duff JL, Monia BP, Berk BC (1995) Mitogen-activated protein (MAP) kinase is regulated by the MAP kinase phosphatase (MKP-1) in vascular smooth muscle cells. *J Biol Chem* 270:7161-7166
- Dulin NO, Alexander LD, Harwalkar S et al (1998) Phospholipase A2-mediated activation of mitogen-activated protein kinase by angiotensin II. *Proc Natl Acad Sci USA* 95:8098-8102
- Dzau V (2005) Cardiovascular continuum and renin-angiotensin-aldosterone system blockade. *J Hypertens* 23(Suppl 1):S9-S18
- Dzau VJ (1988) Circulating versus local renin-angiotensin System in cardiovascular homeostasis. *Circulation* 77(pt II):15-117
- Dzau VJ, Pratt RE (1993) Local Cardiac, Vascular and Renal Renin-Angiotensin Systems in Physiology and Disease. In: Robertson JIS, Nicholls MG (eds) *The Renin-Angiotensin System*. Gower Medical Publishing London New York, vol 1, pp 42.1-42.11
- Endo Y, Arima S, Yaoita H et al (1998) Vasodilation mediated by angiotensin II type 2 receptor is impaired in afferent arterioles of young spontaneously hypertensive rats. *J Vasc Res* 35:421-427
- Erdos EG, Jackman HL, Brovkovich V et al (2002) Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin. *J Mol Cell Cardiol* 34:1569-1576
- Etminan M, Levine MAH, Tomlison G et al (2002) Efficacy of angiotensin II receptor antagonists in preventing headache: A systematic overview and meta-analysis. *Am J Med* 112:642-646
- Fabiani ME, Johnston CI (2001) AT1 Receptor Antagonists as Antihypertensive Agents. In: Epstein M, Brunner HR (eds) *Angiotensin II Receptor Antagonists*. Hanley & Belfus, pp 263-278
- Feng YH, Noda K, Saad Y et al (1995) The docking of Arg2 of Angiotensin II with Asp281 of AT1 receptor is essential for full agonism. *J Biol Chem* 270:12846-12850
- Feng YH, Sun Y, Douglas J (2002) $G_{\beta\gamma}$ -independent constitutive association of G_{α_s} with SHP-1 and angiotensin II receptor AT2 is essential in AT2-mediated ITIM-independent activation of SHP-1. *Proc Natl Acad Sci USA* 99:12049-12054
- Ferguson SSG, Barak LS, Zhang J et al (1996) G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins. *Can J Physiol Pharmacol* 74:1095-1110
- Ferguson AV, Bains JS (1997) Actions of angiotensin in the subfornical organ and the area postrema: implications for long-term control of autonomic output. *Clin Exp Pharmacol Physiol* 24:96-101
- Ferguson SSG (2001) Evolving concepts in G-Protein-Coupled Receptor endocytosis: The role in receptor desensitization and signaling. *Pharmacol Rev* 53:1-24
- Fernandez LA, Caride VJ, Stromberg C et al (1994) Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation. *J Cardiovasc Pharmacol* 24:937-940
- Ferrario CM, Averill DB, Brosnihan KB et al (2004) Angiotensin-(1-7). Its Contribution to Arterial Pressure Control Mechanisms. In: Unger T, Scholkens BA (eds) *Angiotensin*. Springer-Verlag Berlin Heidelberg, vol I, pp 477-518
- Ferrario CM, Jessup J, Chappell MC et al (2005 a) Effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. *Circulation* 111:2605-2610
- Ferrario CM, Trask AJ, Jessup JA (2005 b) Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. *Am J Physiol* 289:H2281-H2290
- Ferrario CM (2006 a) Angiotensin-converting enzyme 2 and Angiotensin-(1-7). An Evolving Story in Cardiovascular Regulation. *Hypertension* 47(pt 2):515-521
- Ferrario CM (2006 b) Role of angiotensin in cardiovascular disease - Therapeutic implications of more than a century of research. *J Renin-Angiotensin-Aldosterone Syst* 7:3-14

- Fierens F, Vanderheyden O, De Baker JP et al (1999) Insurmountable angiotensin II AT1 receptor antagonists: The role of tight antagonist binding. *Eur J Pharmacol* 372:199-206
- Fischer TA, Singh K, O'Hara DS et al (1998) Role of AT1 and AT2 receptors in regulation of MAPK and MKP-1 by ang II in adult cardiac myocytes. *Am J Physiol* 275:H906-H916
- Fitzgerald SM, Evans RG, Bergstrom G et al (1999) Renal hemodynamic responses to intrarenal infusion of ligands for the putative angiotensin IV receptor in anesthetized rats. *J Cardiovasc Pharmacol* 34:206-211
- Fleming I, Kohlstedt K, Busse R (2006) The tissue renin-angiotensin system and intracellular signaling. *Curr Opin Nephrol Hypertens* 15:8-13
- Fletcher AE, Dollery CT (1993) Side Effects Associated with Inhibitors of Angiotensin-Converting Enzyme. In: Robertson JIS, Nicholls MG (eds) *The Renin-Angiotensin System*. Gower Medical Publishing London New York, vol2, pp 99.1-99.15
- Fogari R, Mugellini A, Zoppi A et al (2000) A double-blind, crossover study of the antihypertensive efficacy of angiotensin II-receptor antagonists and their activation of the renin-angiotensin system. *Curr Ther Res* 61:669-679
- Fogari R, Mugellini A, Destro M et al (2006) Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. *J Cardiovasc Pharmacol* 47:46-50
- Fontes MAP, Silva LCS, Campagnole-Santos MJ et al (1994) Evidence that angiotensin-(1-7) plays a role in the central control of blood pressure at the ventrolateral medulla acting through specific receptor. *Brain Res* 665:175-180
- Fontes MAP, Martins Pinge MC, Naves W et al (1997) Cardiovascular effects produced by microinjection of angiotensins and angiotensin antagonists in the ventrolateral medulla of freely moving rats. *Brain Res* 750:305-310
- Fontes MAP, Baltatu O, Caligiorno SM et al (2000) Angiotensin peptides acting at rostral ventrolateral medulla contribute to hypertension of TGR(mREN2)27 rats. *Physiol Genom* 2:137-142
- Forclaz A, Maillard M, Nussberger J et al (2003) Angiotensin II receptor blockade. Is there truly a benefit of adding an ACE inhibitor? *Hypertension* 41:31-36
- Ford WR, Clanachan AS, Lopaschuk GD et al (1998) Intrinsic Ang II type 1 receptor stimulation contributes to recovery of postischemic mechanical function. *Am J Physiol* 43:H11524-H11531
- Forner P, Richer C, Vacher E et al (1993) Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal. *J Cardiovasc Pharmacol* 22:305-313
- Fortuno MA, Ravassa S, Etayo JC et al (1998) Overexpression of Bax protein and enhanced apoptosis in the left ventricle of spontaneously hypertensive rats. Effects of AT1 blockade with Losartan. *Hypertension* 32:280-286
- Foucart S, Patrick SK, Oster L et al (1996) Effects of chronic treatment with Losartan and Enalapril on (3H)-Norepinephrine release from isolated atria of Wistar-Kyoto and spontaneously hypertensive rats. *Am J Hypertens* 9:61-69
- Fournier A, Messerli FH, Achard JM et al (2004) Cerebroprotection mediated by Angiotensin II. A hypothesis supported by recent randomized clinical trials. *J Am Coll Cardiol* 43:1343-1347
- Freedman NJ, Lefkowitz RJ (1996) Desensitization of G-Protein-coupled receptors. *Rec Progr Horm Res* 51:319-351
- Fricker A, Nussberger J, Meilenbrock S et al (1998) Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects. *Kidney Int* 54:2089-2097
- Fridovich I (1997) Superoxide anion radicals, superoxide dismutases and related matters. *J Biol Chem* 272:18515-18517
- Furakawa Y, Kishimoto S, Nishikawa K (1982) Hypotensive imidazole derivatives and hypotensive imidazole-5-acetic acid derivatives. Patents issued to Takeda Chemical Industries Ltd. on July 20, 1982 and October 19, 1982, respectively, U.S. Patents 4,340,598 and 4,355,040, Osaka, Japan, 1982

- Gaborik Z, Szaszak M, Szidonya L et al (2001) β -arrestin and dynamin-dependent endocytosis of the AT1 angiotensin receptor. *Mol Pharmacol* 59:239-247
- Gaborik Z, Jagadeesh G, Zhang M et al (2003) The role of a conserved region of the second intracellular loop in AT1 angiotensin receptor activation and signaling *Endocrinology* 144:2220-2228
- Gallinat S, Yu M, Dorst A et al (1998) Sciatic nerve transection evokes lasting up-regulation of angiotensin AT2 and AT1 receptor mRNA in adult rat dorsal root ganglia and sciatic nerves. *Brain Res* 57:111-122
- Gallinat S, Busche S, Schutze S et al (1999) AT2 receptor stimulation induces generation of ceramides in PC12W cells. *FEBS Lett* 443:75-79
- Gallinat S, Busche S, Raizada MK et al (2000) The angiotensin II type 2 receptor: an enigma with multiple variations. *Am J Physiol* 278:E357-E374
- Gansevoort RT, de Zeeuw D (2000) The antihypertensive and renal effects of angiotensin II receptor antagonists: remaining questions. *Curr Opin Nephrol* 9:57-61
- Gansevoort RT, Mimran A, de Zeeuw D et al (2001) AT1 Receptor Antagonists and the Kidney. In: Epstein M, Brunner HR (eds) *Angiotensin II Receptor Antagonists*. Hanley & Belfus, pp 295-316
- Garcha RS, Sever PS, Hughes AD (1999) Action of AT1 receptor antagonists on angiotensin II-induced tone in human isolated subcutaneous resistance arteries. *Br J Pharmacol* 127:1876-1882
- Garcia-Caballero A, Olivares-Reyes JA, Catt KJ et al (2001) Angiotensin AT1 receptor phosphorylation and desensitization in a hepatic cell line. Role of protein kinase C and Phosphoinositide 3-kinase. *Mol Pharmacol* 59:576-585
- Garcia NH, Garvin JL (1994) Angiotensin 1-7 has a biphasic effect on fluid absorption in the proximal straight tubule. *J Am Soc Nephrol* 5:1133-1138
- Gelband CH, Zhu M, Lu D et al (1997) Functional interaction between neuronal AT1 and AT2 receptors. *Endocrinology* 138:2195-2198
- Gether U, Kobilka BK (1998) G protein-coupled receptors: II. Mechanism of agonist activation. *J Biol Chem* 273:17979-17982
- Gigante B, Piras O, De Paolis P et al (1998) Role of angiotensin II AT2-subtype receptors in the blood pressure lowering effect of Losartan in salt-restricted rats. *J Hypertens* 16:2039-2043
- Gironacci MM, Vatta M, Rodriguez-Fermepin M et al (2000) Angiotensin-(1-7) reduces norepinephrine release through a nitric oxide mechanism in rat hypothalamus. *Hypertension* 35:1248-1252
- Glossmann H, Baukal A, Catt KJ (1974) Properties of angiotensin II in bovine and rat adrenal cortex. *J Biol Chem* 249:825-831
- Gohlke P, Pees C, Unger T (1998) AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a Kinin-dependent mechanism. *Hypertension* 31:349-355
- Gohlke P, Scholkens BA (2004) ACE Inhibitors: Pharmacology. In: Unger T, Scholkens BA (eds) *Angiotensin*. Springer-Verlag Berlin Heidelberg, vol II, pp 375-413
- Goldenbergh I, Grossman E, Jacobson KA et al (2001) Angiotensin-induced apoptosis in rat cardiomyocyte culture: a possible role of AT1 and AT2 receptors. *J Hypertens* 19:1681-1689
- Gomez-Cambronero J, Kiere P (1998) Phospholipase D: A novel major player in signal transduction. *Cell Signal* 10:387-397
- Goodfriend TL, Lin SY (1970) Receptors for Angiotensin I and II. *Circ Res* 26 and 27 S.1:1-163
- Goodfriend TL (2000) Angiotensin receptors: Hystory and mysteries. *Am J Hypertens* 13:442-449
- Gorelik G, Carhini LA, Scicli AG (1998) Angiotensin-(1-7) induces bradykinin-mediated relaxation in porcine coronary artery. *J Pharmacol Exp Ther* 286:403-410
- Grady EF, Sechi LA, Griffin CA et al (1991) Expression of AT2 receptors in the developing rat fetus. *J Clin Invest* 88:921-933

- Griendling KK, Ushio-Fukai M, Lassegue B et al (1997) Angiotensin II signaling in vascular smooth muscle. *New Concepts. Hypertension* 29(pt 2):366-373
- Griendling KK, Ushio-Fukai M (2000) Reactive oxygen species as mediators of angiotensin II signaling. *Regul Pept* 91:21-27
- Griffin SA, Brown WCB, MacPherson F et al (1991) Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. *Hypertension* 17:626-635
- Griffiths CD, Morgan TO, Delbridge LM (2001) Effects of combined administration of ACE inhibitor and angiotensin II receptor antagonist are prevented by a high salt intake. *J Hypertens* 19:2087-2095
- Grone HJ, Simon M, Fuchs E (1992) Autoradiographic characterization of angiotensin receptor subtypes in fetal and adult kidney. *Am J Physiol* 262:F32-F331
- Gros R, Benovic JL, Tan CM et al (1997) G-protein-coupled receptor kinase is increased in hypertension. *J Clin Invest* 99:2087-2093
- Gross V, Schunk WH, Honeck H et al (2000) Inhibition of pressure natriuresis in mice lacking AT2 receptor. *Kidney Int* 57:191-202
- Gross V, Obst M, Luft FC (2004) Insights into angiotensin II receptor function through AT2 receptor knockout mice. *Acta Physiol Scand* 181:487-494
- Haendeler J, Berk BC (2000) Angiotensin II-mediated signal transduction. Important role of tyrosine kinases. *Regul Pept* 95:1-7
- Haendeler J, Dimmeler S (2004) Regulation of Angiogenesis by Angiotensin II. In: Unger T, Scholkens BA (eds) *Angiotensin*. Springer-Verlag Berlin Heidelberg, vol I, pp 99-109
- Hamawaki M, Coffman TM, Lashus A et al (1998) Pressure-overload hypertrophy is unabated in mice devoid of AT1A receptors. *Am J Physiol* 274:H868-H873
- Hamet P, Richard L, Dam TV et al (1995) Apoptosis in target organs of hypertension. *Hypertension* 26:642-648
- Hamilton TA, Handa RK, Harding JW et al (2001) A role for the angiotensin IV/ AT4 System in mediating natriuresis in the rat. *Peptides* 22:935-944
- Handa RK, Ferrario CM, Strandhoy JW (1996) Renal actions of angiotensin-(1-7): in vivo and in vitro studies. *Am J Physiol* 270:F141-F147
- Handa RK, Krebs LT, Harding JW et al (1998) Angiotensin IV AT4-receptor System in the rat kidney. *Am J Physiol* 274:F290-F299
- Handa RK (1999) Angiotensin-(1-7) can interact with the rat proximal tubule receptor System. *Am J Physiol* 277:F75-F83
- Handa RK (2001) Characterization and signaling of the AT(4) receptor in the human proximal tubule epithelial (HK-2) cells. *J Am Soc Nephrol* 12:440-449
- Hanesworth JM, Sardinia MF, Krebs LT et al (1993) Elucidation of a specific binding site for angiotensin II(3-8), angiotensin IV, in mammalian heart membranes. *J Pharmacol Exp Ther* 46:1510-1512
- Hanley MR (1991) Molecular and cell biology of angiotensin receptors subtypes. *J Cardiovasc Pharmacol* 18(S 2):S7-S13
- Hansen J, Servant G, Baranski T et al (2000) Functional reconstitution of the angiotensin II type 2 receptor and G(i) activation. *Circ Res* 87:753-759
- Hansson L, Lindholm LH, Niskanen L et al (1999 a) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. *Lancet* 353:611-616
- Hansson L, Lithell H, Skoog I et al (1999 b) Study on Cognition and Prognosis in the Elderly (SCOPE). *Blood Press* 8:177-183
- Hansson L, Lithell H, Skoog I et al (2000) Study on Cognition and Prognosis in the Elderly (SCOPE): baseline characteristics. *Blood Press* 9:146-151
- Harada K, Komuro I, Shiojima I et al (1998) Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. *Circulation* 97:1052-1059
- Harada K, Sugaya T, Murakami K et al (1999 a) Angiotensin type 1A receptor knockout mi-

- ce display less ventricular remodelling and improved survival after myocardial infarction. *Circulation* 100:2093-2099
- Harada K, Komuro I, Sugaya T et al (1999 b) Vascular injury causes neointimal formation in angiotensin II type 1a receptor knockout mice. *Circ Res* 84:179-135
- Harris RC (2001) Signaling and Cellular Effects of Angiotensin II. In: Epstein M, Brunner HR (eds) *Angiotensin II Receptor Antagonists*. Hanley & Belfus, pp 49-53
- Harrison-Bernard LM, Navar LG, Ho MM et al (1997) Immunohistochemical localization of Ang II AT1 receptor in adult rat kidney using a monoclonal antibody. *Am J Physiol* 273:F170-F177
- Hashimoto N, Maeshima Y, Satoh M et al (2003) Overexpression of angiotensin type-2 receptor ameliorates glomerular injury in a mouse remnant kidney model. *Am J Physiol* 286:F516-F525
- Haulica I, Bild W, Serban DN (2005) Angiotensin peptides and their pleiotropic actions. *J Renin-Angiotensin-Aldosterone Syst* 6:121-131
- Hayashida W, Horiuchi M, Dzau VJ (1996) Intracellular third loop domain of angiotensin II type 2 receptor. *J Biol Chem* 271:21985-21992
- Heagerty AM (2005) Influence of changes of blood pressure on vascular angiotensin II receptor subtype expression. *Circulation* 111:956-957
- Hedner T, Himmelmann A (1999) The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group. *J Hypertens* 17:129-136
- Hein L, Barsh GS, Pratt RE et al (1995) Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. *Nature* 377:744-747
- Hein L, Meinel L, Pratt RE et al (1997 a) Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: Evidence for selective sorting of receptor and ligand. *Mol Endocrinol* 11:1266-1277
- Hein L, Stevens ME, Barsh GS et al (1997 b) Overexpression of the AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. *Proc Natl Acad Sci USA* 94:6391-6396
- Heitsch H, Brovkovich S, Malinsky T et al (2001) Angiotensin-(1-7)-stimulated nitric oxide and superoxide release from endothelial cells. *Hypertension* 37:72-76
- Henderson IN, Deacon CF (1993) Phylogeny and comparative Physiology of the Renin-Angiotensin System. In: Robertson JIS, Nicholls MG (eds) *The Renin-Angiotensin System*. Gower Medical Publishing London, vol 1, pp 2.01-2.28
- Henrion D, Kubis N, Levy BL (2001) Physiological and pathophysiological functions of the AT2 subtype receptor of angiotensin II. From large arteries to microcirculation. *Hypertension* 38:1150-1157
- Herdling J, Hines J, Fluharty S et al (2001) Identification and function of disulfide bridges in the extracellular domains of the angiotensin II type 2 receptor. *Biochemistry* 40:8369-8377
- Heuser JE, Anderson RG (1989) Hypertonic media inhibit receptor-mediated endocytosis by blocking clathrin-coated pit. *J Biol Chem* 264:389-400
- Himmelmann A, Keinanen-Kiukkaanniemi S, Wester A et al (2001) The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily in patients with mild or moderate hypertension. For the EFFECT Study Group. *Blood Press* 10:43-51
- Hines J, Heerding J, Fluharty S et al (2001) Identification of angiotensin II type 2 (AT2) receptor domains mediating high-affinity CGP 42112A binding and receptor activation; *J Pharmacol Exp Ther* 298:665-673
- Hirano T, Ran J, Adachi M (2006) Opposing actions of angiotensin II type 1 and 2 receptors on plasma cholesterol levels in rats. *J Hypertens* 24:103-108
- Hoffmann S, Krause T, Pinto Y et al (1996) Cardiac-specific expression of the human AT1 receptor in transgenic rats. *Hypertension* 28:P76 (abstract)
- Hohle S, Culman J, Boser M et al (1996) Effect of angiotensin AT2 and muscarinic receptor blockade on osmotically induced vasopressin release. *Eur J Pharmacol* 300:119-123

- Horiuchi M, Hayashida W, Kambe T et al (1997) Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase Phosphatase-1 and induces apoptosis. *J Biol Chem* 272:19022-19026
- Horiuchi M, Akishita M, Dzau VJ (1998) Molecular and cellular mechanism of angiotensin II-mediated apoptosis. *Endocr Res* 24:307-314
- Horiuchi M, Hayashida W, Akishita M et al (1999 a) Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative cross-talk. *Circ Res* 84:876-882
- Horiuchi M, Akishita M, Dzau VJ (1999 b) Recent progress in angiotensin II type 2 receptor research in the cardiovascular System. *Hypertension* 33:613-621
- Hornig B, Landmesser U, Kohler C et al (2001) Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. *Circulation* 103:799-805
- Hu L, Catanzaro DF, Laragh JH et al (1999) Delayed recovery of hypertension after single dose of Losartan in angiotensin II-infused conscious rats. *J Hypertens* 17:1443-1450
- Huang X-C, Richards EM, Sumners C (1996) Mitogen-activated protein kinases in rat brain neuronal cultures are activated by angiotensin II type 1 receptor and inhibited by angiotensin II type 2 receptor. *J Biol Chem* 271:15635-15641
- Humphrey PPA, Bernard EA (1998) International Union of Pharmacology. The IUPHAR receptor code: a proposal for an alphanumeric classification System. *Pharmacol Rev* 50:271-277
- Hunyady L, Baukal AJ, Balla T et al (1994a) Independence of type 1 angiotensin II receptor endocytosis from G protein coupling and signal transduction. *J Biol Chem* 269:24798-24804
- Hunyady L, Bor M, Balla T et al (1994b) Identification of a cytoplasmic Ser-Thr-Leu motif that determines agonist-induced internalization of the AT1 angiotensin receptor. *J Biol Chem* 269:31378-31382
- Hunyady L, Balla T, Catt K (1996) The ligand binding site of the angiotensin AT1 receptor. *Trends Pharmacol Sci* 17:135-140
- Hunyady L (1999) Molecular mechanisms of angiotensin II receptor internalization. *J Am Soc Nephrol* 10:S47-S56
- Hunyady L, Catt KJ, Clark AJL et al (2000) Mechanisms and functions of AT1 angiotensin receptor internalization. *Regul Pept* 91:29-44
- Hunyady L, Gaborik Z, Vauquelin G et al (2001) Structural requirements for signaling and regulation of AT1-receptors. *J Renin-Angiotensin-Aldosterone Syst* 2 (S1):S16-S23
- Hunley TE, Tamura M, Stoneking BJ et al (2000) The angiotensin type II receptor tonically inhibits angiotensin converting enzyme in AT2 null mutant mice. *Kidney Int* 57:570-577
- Ichihara S, Senbonmatsu T, Price E jr et al (2001) Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. *Circulation* 104:346-351
- Ichiki T, Kambayashi Y, Inagami T (1995 a) Multiple growth factors modulate messenger RNA expression of angiotensin II type 2 receptor in R3T3 cells. *Circ Res* 77:1070-1076
- Ichiki T, Labosky PA, Shiota C et al (1995 b) Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. *Nature* 377:748-750
- Igase M, Strawn WB, Gallagher PE et al (2005) Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. *Am J Physiol* 289:H1013-H1019
- Inagami T (1995) Recent progress in molecular and cell biological studies of angiotensin receptors. *Curr Opin Nephrol Hypertens* 4:47-54
- Inagami T (1999 a) Molecular biology and signaling of angiotensin receptors. An overview. *J Am Soc Nephrol* 10:S2-S7
- Inagami T, Eguchi S, Numaguchi K et al (1999 b) Cross-talk between angiotensin II receptors and the tyrosine kinases and phosphatases. *J Am Soc Nephrol* 10:S57-S61
- Inagami T, Mizukoshi M, Guo Den-Fu (1994) Angiotensin II Receptor: Molecular Cloning,

- Functions, and Regulation. In: Saavedra JM, Timmermans PBMWM (eds): *Angiotensin Receptors*. Plenum Press, Newyork and London pp 1-15
- Innocenti AD, Elmfeldt D, Hansson L et al (2002) Cognitive function and health-related quality of life in elderly patients with hypertension – baseline data from the Study on Cognition and Prognosis in the Elderly. *Blood Press* 11:157-162
- Inoue Y, Nakamura N, Inagami T (1997) A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of agonist and antagonist binding site and the hypothesis of a receptor activation mechanism. *J Hypertens* 15:703-714
- Ishizaka N, Griendling KK, Lassegue B et al (1998) Angiotensin type 1 receptor Relationship with caveole and caveolin after initial agonist stimulation. *Hypertension* 32:459-466
- Ito M, Oliverio MI, Mannon PJ et al (1995) Regulation of blood pressure by the type 1A angiotensin receptor gene. *Proc Ntl Acad Sci USA* 92:3521-3525
- Iyer SN, Ferrario CM, Chappell MC (1998) Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin System. *Hypertension* 31:356-361
- Iyer SN, Yamada K, Diz DI et al (2000) Evidence that prostaglandins mediate the antihypertensive action of angiotensin-(1-7) during chronic blockade of the renin-angiotensin system. *J Cardiovasc Pharmacol* 36:109-117
- Jackson TR, Blair LA, Marshall J et al (1988) The mas oncogene encodes an angiotensin receptor. *Nature* 335:437-440
- Jaiswal N, Diz DI, Tallant EA et al (1991) Characterization of angiotensin receptors in mediating prostaglandins synthesis in C6 glioma cells. *Am J Physiol* 260:R1000-R1006
- Jaiswal N, Tallant EA, Jaiswal RK et al (1993) Differential regulation of prostaglandins synthesis by angiotensin peptides in porcine aortic smooth muscle cells: Subtypes of angiotensin receptors involved. *J Pharmacol Exp Ther* 265:664-673
- Ji H, Leung M, Zhang Y et al (1994) Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT₁angiotensin receptor. *J Biol Chem* 269:16533-16536
- Jimenez AM, Monton M, Garcia R et al (2001) Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: Comparison of Losartan, Candesartan, Valsartan. *J Cardiovasc Pharmacol* 37:406-412
- Jin XH, Wang ZQ, Siragy HM et al (1998) Regulation of jejunal sodium and water absorption by angiotensin subtype receptors. *Am J Physiol* 275:R515-R523
- Jin XH, Siragy HM, Carey RM (2001) Renal interstitial cGMP mediates natriuresis by direct tubule mechanism. *Hypertension* 38:309-316
- Johansson ME, Wickman A, Fitzgerald SM et al (2005) Angiotensin II type 2 receptor is not involved in the angiotensin II-mediated pro-atherogenic process in ApoE^{-/-} mice. *J Hypertens* 23:1541-1549
- Julian BA, Brantley RR, Barker CV et al (1998) Losartan, an angiotensin II type 1 antagonist, lowers hematocrit in post-transplant erythrocytosis. *J Am Soc Nephrol* 9:1104-1108
- Johnson AK, Gross PM (1993) Sensory circumventricular organs and brain homeostatic pathways. *FASEB J* 7:678-686
- Julius S, Kjeldsen SE, Weber M et al (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan or amlodipine-based regimens: VALUE, a randomized trial. *Lancet* 363:2021-2031
- Kai H, Alexander RW, Ushio-Fukai M et al (1998) G-Protein binding domains of the angiotensin AT_{1A} receptors mapped with synthetic peptides selected from the receptor sequence. *Biochem J* 332:781-787
- Kakinuma Y, Hama H, Sugiyama E et al (1997) Anti-apoptotic action of angiotensin fragments to neuronal cells from angiotensinogen knockout mice. *Neurosci Lett* 232:167-170
- Kakuchi J, Ichiki T, Kiyama S et al (1995) Developmental expression of renal angiotensin receptor gene in the mouse. *Kidney Int* 47:140-147
- Kalenga MK, de Gasparo M, de Hertogh M et al (1991) Angiotensin II receptors in the placenta are type 1. *Reprod Nutr Dev* 31:257-267

- Kambayashi Y, Takahashi K, Bardhan S et al (1994) Molecular structure and function of angiotensin type 2 receptor. *Kidney Int* 46:1502-1504
- Kang J, Posner P, Sumners C (1994) Angiotensin II type 2 receptor stimulation of neuronal K⁺ currents involves an inhibitory GTP binding protein. *Am J Physiol* 267:C1389-C1397
- Kario K, Nishikimi T, Yoshihara F et al (1998) Plasma levels of natriuretic peptides and adrenomedullin in elderly hypertensive patients: relationships to 24h blood pressure. *J Hypertension* 16:1253-1259
- Karnik SS, Husain A, Graham RM (1996) Molecular determinants of peptide and non peptide binding to the AT1 receptor. *Clin Exp Pharmacol Physiol* (S3):S58-S66
- Kaschira E, Unger T (2003) Angiotensin AT1/AT2 receptors: Regulation, signaling and function. *Blood Press* 12:70-88
- Kassler-Taub K, Littlejohn T, E11iott W et al (1998) Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. *Am J Hypertens* 11:445-453
- Katada J, Majima M (2002) AT2 receptor-dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions. *Br J Pharmacol* 136:484-491
- Kerr JF, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br J Cancer* 26:239-257
- Kimura B, Sumners C, Phillips MI (1992) Changes in skin angiotensin II receptors in rats during wound healing. *Biochem Biophys Res Commun* 187:1083-1090
- Koh KK, Ahn JY, Han SH et al (2003) Pleiotropic effects of angiotensin II receptor blockers in hypertensive patients. *J Am Coll Cardiol* 42:905-910
- Koike G, Horiuchi M, Yamada T et al (1994) Human type 2 angiotensin II receptor gene: cloned, mapped to X chromosome and its mRNA is expressed in human lung. *Biochem Biophys Res Commun* 203:1842-1850
- Kong JY, Rabkin SW (2000) Angiotensin II does not induce apoptosis but rather prevents apoptosis in cardiomyocytes. *Peptides* 21:1237-1247
- Kostenis E, Milihan G, Christopoulos D et al (2005) G-Protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. *Circulation* 111:1806-1816
- Kramar EA, Krishnan R, Harding JW et al (1998) Role of nitric oxide in angiotensin IV-induced increases in cerebral blood flow. *Regul Pept* 74:185-192
- Kramer C, Sunkomat J, Witte J et al (2002) Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of Losartan. Role of the active metabolite EXP 3179. *Circ Res* 90:770-776
- Kuba K, Imai Y, Rao S et al (2005) A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med* 11:875-879
- Kule CE, Karoor V, Day JNE et al (2004) Agonist-dependent internalization of the angiotensin II type one receptor (AT1): role of C-terminus phosphorylation in recruitment of B-arrestins. *Regul Pept* 120:141-148
- Kumagai K, Reid IA (1994) Losartan inhibits sympathetic and cardiovascular responses to carotid occlusion. *Hypertension* 23 (pt 2):827-831
- Kurabayashi M, Yazaki Y, (1997) Down-regulation of angiotensin II receptor type 1 in heart failure: A process of adaptation or deterioration? *Circulation* 95:1104-1107
- Kurusu S, Ozono R, Oschima T et al ((2003) Cardiac angiotensin II type 2 receptor activates the kinin/NO System and inhibits fibrosis. *Hypertension* 41:99-107
- Kurz TW, Pravenec M (2004) Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin receptors antagonists: Beyond the renin-angiotensin System. *J Hypertens* 22:2253-2261
- Lacour C, Canals F, Galindo G et al (1994) Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive models. *Eur J Pharmacol* 264:307-316
- Lacourcière Y, Brunner H, Irwin R et al (1994) Effects of modulators of the renin-angiotensin-aldosterone System on cough. Losartan Cough Study Group. *J Hypertens* 12:1387-1393

- Laflamme L, de Gasparo M, Gallo JM et al (1996) Angiotensin II induction of neurite outgrowth by AT₂ receptors in NG108-15 cells. Effect counteracted by the AT₁ receptors. *J Biol Chem* 271:22729-22735
- Lassegue B, Alexander RW, Nickenig G et al (1995) Angiotensin II down-regulates the vascular smooth muscle AT₁ receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation. *Mol Pharmacol* 48:601-609
- Laursen JB, Rajagopalan S, Galis Z et al (1997) Role of superoxide in angiotensin-induced but not catecholamine-induced hypertension. *Circulation* 95:588-593
- Leclerc PC, Auger Messier M, Lanctot PM et al (2002) A polyaromatic caveolin-binding-like motif in the cytoplasmic tail of the type 1 receptor for angiotensin II plays an important role in receptor trafficking and signaling. *Endocrinology* 143:4702-4710
- Le MT, Vanderheyden P, Szaszak M et al (2002) Angiotensin IV is a potent agonist for constitutive active human AT₁ receptors: distinct role of the N- and C-terminal residues of angiotensin II during AT₁ receptor activation. *J Biol Chem* 277:23107-23110
- Lee J, Chay SY, Mendelsohn FA et al (2001) Potentiation of cholinergic transmission in the rat hippocampus by angiotensin IV and LVV-hemorphin-7. *Neuropharmacology* 40:618-623
- Lee VC, Rhew DC, Dylan M et al (2004) Meta-analysis: Angiotensin Receptor blockers in chronic heart failure and high-risk acute myocardial infarction. *Ann Intern Med* 141:693-704
- Lefkowitz RJ (1998) G-protein-coupled receptors. III: New roles for receptor kinases and β -arrestins in receptor signaling and desensitization. *J Biol Chem* 273:18677-18680
- Lethonen JYA, Daviet L, Nahmias C et al (1999) Analysis of functional domains of angiotensin II type 2 receptor involved in apoptosis. *Mol Endocrinol* 13:1051-1060
- Leung PS, Sernia C (2003) The renin-angiotensin System and male reproduction: new functions for old hormones. *J Mol Endocrinol* 30:263-270
- Levy BI, Benessiano J, Henrion D et al (1996) Chronic blockade of AT₂-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. *J Clin Invest* 98:418-425
- Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 345:851-860
- Li Jin-S, Sharif AM, Schiffrin EL (1997) Effect of AT₁ angiotensin-receptor blockade on structure and function of small arteries in SHR. *J Cardiovasc Pharmacol* 30:75-83
- Li P, Chappell MC, Ferrario CM et al (1997) Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. *Hypertension* 29(pt 2):394-400
- Li DY, Yang BC, Philips MI et al (1999) Proapoptotic effects of Ang II in human coronary artery endothelial cells: role of AT₁ receptor and PKC activation. *Am J Physiol* 276:H786-H792
- Li WL, Moore MJ, Vasilieva N et al (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* 426:452-454
- Li Z, Iwai M, Wu L et al (2003) Role of AT₂ receptor in the brain in the regulation of blood pressure and water intake. *Am J Physiol* 284:H116-H121
- Lima CV, Paula RD, Resende FL et al (1997) Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats. *Hypertension* 30 (pt 2):542-548
- Lindholm LH, Ibsen H, Borch-Johnsen K et al (2002) Risk of new-onset diabetes in the Losartan Intervention for Endpoint reduction in hypertension study. *J Hypertens* 20:1879-1886
- Lithell H, Hansson L, Skoog I et al for the SCOPE Study Group (2003) The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. *J Hypertens* 21:875-886
- Liu Y-H, Yang X-P, Sharov VG et al (1997) Effect of angiotensin-converting enzyme inhibitors and angiotensin type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. *J Clin Invest* 99:1926-1935

- Lo M, Liu K-L, Lantelme P et al (1995 a) Subtype 2 of angiotensin II receptors control pressure-natriuresis in rats. *J Clin Invest* 95:1394-1397
- Lo M, Goldberg MR, McCrea JB et al (1995 b) Pharmacokinetics of Losartan, an angiotensin receptor antagonist and its active metabolite EXP 3174 in humans. *Clin Pharmacol Ther* 58:641-649
- Loufrani L, Henrion D, Chansel Q et al (1999) Functional evidence for an angiotensin IV receptor in rat resistance arteries. *J Pharmacol Exp Ther* 291:583-588
- Lucius R, Gallinat S, Rosenstiel P et al (1998) The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. *J Exp Med* 188:661-670
- Maillard MP, Wurzner G, Nussberger J et al (2002) Comparative angiotensin II receptor blockade in healthy volunteers: The importance of dosing. *Clin Pharmacol Ther* 71:68-76
- Maillard M, Burnier M (2004) Clinical Pharmacology of Angiotensin II Receptor Antagonists. In: Unger T, Scholkens BA (eds) *Angiotensin*. Springer-Verlag Berlin Heidelberg, vol II, pp 453-484
- Mallion JM, Goldberg AI (1996) Global efficacy and tolerability of Losartan an angiotensin II subtype 1-receptor antagonist in the treatment of hypertension. *Blood Press* 5 (S 2):82-86
- Mancia G, Dell'Oro R, Quarti-Treviso F et al (2006) Angiotensin-sympathetic interactions in cardiovascular and metabolic disease. *J Hypertens* 24 (S 1):S51-S56
- Mann J, Julius S (1998) The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. *Blood Press* 7:176-183
- Marrero M, Venema V, Ju H et al (1998) Regulation of angiotensin-induced JAK2 tyrosine Phosphorylation; roles of SHP-1 and SHP-2. *Am J Physiol* 275:C1216-C1223
- Masaki H, Kurihara P, Yamaki A et al (1998) Cardiac-specific overexpression of Angiotensin II AT2 receptor causes attenuated response to AT1-mediated pressor and chronotropic effects. *J Clin Invest* 101:527-535
- Matos de Moura M, Santos RAS, Peliky Fontes MA (2005) Evidence for a functional cardiac interaction between losartan and angiotensin-(1-7) receptors revealed by orthostatic tilting test in rats. *Br J Pharmacol* 144:755-760
- Matsubara H (1998) Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal disease. *Circ Res* 83:1182-1191
- Matsusaka T, Nishimura H, Utsunomiya H et al (1996) Chimeric mice carrying "regional" targeted deletion of the angiotensin type 1A receptor gene: evidence against the role for local angiotensin in the in vivo feedback regulation of renin synthesis in juxtaglomerular cells. *J Clin Invest* 98:1867-1877
- Mazzolai L, Maillard M, Rossat J et al (1999) Angiotensin II receptor blockade in normotensive subjects: a direct comparison of three AT1 receptor antagonists. *Hypertension* 35:850-855
- Mazzolai L, Burnier M (2001) Angiotensin Receptor Antagonists: Safety and tolerability Profile. In: Epstein M, Brunner HR (eds). *Angiotensin II Receptor Antagonists*. Hanley & Belfus Phi., pp 339-350
- McClellan KJ, Markham A (1998 a) Telmisartan. *Drugs* 56:1039-1046
- McClellan KJ, Balfour JA (1998 b) Eprosartan. *Drugs* 55:713-718
- McKelvie RS, Yusuf S, Pericak D et al (1999) Comparison of candesartan, enalapril and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. *Circulation* 100:1056-1064
- McKinley MJ, Albiston AL, Allen AM et al (2003) The brain renin-angiotensin system: location and physiological role. *Int J Biochem Cell Biol* 35:901-918
- McInness GT (2005) Lowering blood pressure for cardiovascular risk reduction. *J Hypertens* 23 (Suppl 1):S3-S8
- McMurray JJV, Ostergren J, Swedberg K et al (2003 a) Effects of Candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-added trial. *Lancet* 362:767-771

- McMurray JJV, Ostergren J, Pfeffer M et al (2003 b) Clinical features and contemporary management of patients with low and preserved ejection heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. *Eur J Heart Fail* 5:261-270
- Meffert S, Stoll M, Steckelings UM et al (1996) The angiotensin AT₂ receptor inhibits proliferation and promotes differentiation in PC12W cells. *Mol Cell Endocrinol* 122:59-67
- Menard J, Azizi M (2004) Renin angiotensin System blockade: to what extent? *J Hypertens* 22:459-462
- Meredith PA (2000) ACE inhibition and AT₁ receptor blockers: efficacy and duration in hypertension. *Heart* 84 (S 1):139-141
- Messerli FH, Chiadika SM (2005) Stroke prevention: not all antihypertensive drugs are created equal. *J Renin-Angiotensin-Aldosterone Syst* 6 (S 1):S4-S11
- Metha JL, Li DY, Yang H et al (2002) Angiotensin II and IV stimulate expression and release of plasminogen activator inhibitor-1 in cultured human coronary artery endothelial cells. *J Cardiovasc Pharmacol* 39:789-794
- Meszáros JG, Raphael R, Lio FM et al (2000) Protein kinase C contributes to desensitization of angiotensin II signaling in adult rat cardiac fibroblasts. *Am J Physiol* 279:C1978-C1985
- Meyer P, Papadimitriou A, Worcel M (1970) Possible existence of different types of angiotensin receptors. *Br J Pharmacol* 40:541P
- Miyazaki Y, Wada T, Shiota N et al (1999) Effects of an angiotensin II receptor antagonist, Candesartan cilexetil, on canine intima hyperplasia after balloon injury. *J Hypertens* 13 (S 1):S21-S25
- Miyazaki Y, Ichikawa I (2001) Role of the angiotensin receptor in the development of the mammalian kidney and urinary tract. *Comp Biochem Physiol A, Mol Integr Physiol* 128:89-97
- Miura S, Karnik SS (1999) Angiotensin II type 1 and type 2 receptors bind angiotensin through different types of epitope recognition. *J Hypertens* 17:397-404
- Miura S, Karnik SS (2000) Ligand-independent signals from angiotensin II type 2 receptor induce apoptosis. *EMBO J* 19:4026-4035
- Miura S, Karnik SS, Saku K (2005) Constitutively active homo-oligomeric angiotensin II type 2 receptor induces cell signaling independent of receptor conformation and ligand stimulation. *J Biol Chem* 280:18237-18244
- Moeller I, Lew RA, Mendelsohn FAO et al (1997) The globin fragment LVV-hemorphin-7 is an endogenous ligand for the AT₄ receptor in the brain. *J Neurochem* 68:2530-2537
- Moeller I, Clune EF, Fennessy PA et al (1999) Up regulation of AT₄ receptor levels in carotid arteries following balloon injury. *Regul Pept* 83:25-30
- Mogensen CE, Neldam S, Tikkanen I et al (2000) Randomized controlled trial of dual blockade of renin-angiotensin System in patients with hypertension, microalbuminuria and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. *BMJ* 321:1440-1444
- Monnot C, Weber V, Stinnakre J et al (1991) Cloning and functional characterization of a novel mas-related gene, modulating intracellular angiotensin II actions. *Mol Endocrinol* 5:1477-1487
- Moore AF, Heiderstadt NT, Huang E et al (2001) Selective inhibition of the renal angiotensin type 2 receptor increases blood pressure. *Hypertension* 37:1285-1291
- Moravski CJ, Kekky DJ, Cooper ME et al (2000) Retinal macrovascularization is prevented by blockade of the renin-angiotensin System. *Hypertension* 36:1099-1104
- Morgan T, Anderson A, Bertram D et al (2004) Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria. *J Renin—Angiotensin-Aldosterone Syst* 5:64-71
- Morganti A (2006) Randomized clinical trials on surrogate endpoints: Are they useful for evaluating cardiovascular and renal disease protection in hypertension? The case for yes. *J Am Soc Nephrol* 17:S141-S144
- Moriuchi R, Shibata S, Himeno A et al (1998) Molecular cloning and pharmacological cha-

- acterization of an atypical gerbil angiotensin II type-1 receptor and its mRNA expression in brain and peripheral tissues. *Mol Brain Res* 60:234-246
- Moroi M, Fukarawa M, Ishikawa M et al (1997) Stimulation of angiotensin subtype 2 receptor reduces basal cGMP levels in the neointima of rat aorta after balloon injury. *Gen Pharmacol* 28:113-117
- Morris M, Means S, Oliverio MI et al (2001) Enhanced central response to dehydration in mice lacking angiotensin AT1A receptors. *Am J Physiol* 280:R1177-R1184
- Moulik S, Speth RC, Rowe BP (2000) Differential loss in function of angiotensin receptor subtypes during tissue storage. *Life Sci* 66:PL233-PL237
- Mukoyama M, Nakajima M, Horiuchi M et al (1993) Expression cloning of type 2 angiotensin receptor reveals a unique class of seven-transmembrane receptors. *J Biol Chem* 268:24539-24542
- Munzenmaier DH, Greene AS (1995) Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. *Hypertension* 27:760-765
- Munzenmaier DH, Greene AS (2006) Chronic angiotensin II AT1 receptor blockade increases cerebral cortical microvessels density. *Am J Physiol* 290:H512-H516
- Muratani H, Ferrario CM, Averill DB (1993) Ventrolateral medulla in spontaneously hypertensive rats: role of angiotensin II. *Am J Physiol* 264:R388-R395
- Murphy TJ, Alexander RW, Griendling KK et al (1991) Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. *Nature* 351:233-236
- Mustafa T, Lee JH, Chay SY et al (2001) Bioactive angiotensin peptides: focus on Angiotensin IV. *J Renin-Angiotensin-Aldosterone Syst* 2:205-210
- Muthalif MM, Benter IF, Uddin MR et al (1998) Signal transduction mechanisms involved in angiotensin-(1-7)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cell. *J Pharmacol Exp Ther* 284:388-398
- Nahmias C, Boden C (2004) Molecular Aspects of AT2 Receptor. In: Unger T, Scholkens BA (eds) *Angiotensin*. Springer-Verlag Berlin Heidelberg, vol 1, pp 375-397
- Nakajima M, Hutchinson HG, Fujinaga M et al (1995) The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. *Proc Natl Acad USA* 92:10663-10667
- Nakamura S, Averill DB, Chappell MC et al (2002) Contribution of angiotensin receptor subtypes to blood pressure regulation in salt depleted spontaneously hypertensive rats. *FASEB J* 1284:R164-R173
- Nakashima M, Uemats T, Kosuge K et al (1992) Pilot study of the uricosuric effect of DuP 753, a new angiotensin receptor antagonist, in healthy subjects. *Eur J Clin Pharmacol* 42:333-335
- Nasjletti A (1998) The role of eicosanoids in angiotensin-dependent hypertension. *Hypertension* 31 (pt 2):194-200
- Naveri L (1995) The role of angiotensin receptor subtypes in cerebrovascular regulation in the rat. *Acta Physiol Scand* 155 (S 630):1-48
- Nickenig G, Baumer AT, Temur Y et al (1999) Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. *Circulation* 100:2131-2134
- Nishimura H, Tsuji H, Masuda H et al (1997) Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. *Thromb Haemost* 77:1189-1195
- Nishimura H, Yerkes E, Hohenfellner K et al (1999) Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men. *Mol Cell* 3:1-10
- Nishimura Y, Ito T, Saavedra JM (2006) Angiotensin II AT1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. *Stroke* 31:2478-2486
- Nishimura H (2004) Phylogeny and Ontogeny of the Renin-Angiotensin System. In: Unger T, Scholkens BA (eds) *Angiotensin*. Springer-Verlag Berlin Heidelberg, vol 1, pp 31-70

- Noda K, Saad Y, Karnik SS (1995) Interaction of Phe⁸ of angiotensin II with Lys¹⁹⁹ and His²⁵⁶ of the AT₁ receptor in agonist activation. *J Biol Chem* 270:28511-28514
- Noda K, Feng YH, Liu Xp et al (1996) The active state of the AT₁ angiotensin receptor is generated by angiotensin II induction. *Biochemistry* 35:16435-16442
- Nora EH, Munzenmaier DH, Hansen-Smith FM et al (1998) Localization of the ANG II type 2 receptor in the microcirculation of skeletal muscle. *Am J Physiol* 275:H1395
- Nossaman BD, Feng CJ, Kaye AD et al (1995) Analysis of responses to Ang IV: Effects of PD123319 and DuP 753 in the pulmonary circulation of the rat. *Am J Physiol* 268:L303-L308
- Nouet S, Amzallag N, Li J-M et al (2004) Trans-inactivation of receptor tyrosine kinases by novel Angiotensin II AT₂ receptor-interacting protein, ATIP. *J Biol Chem* 279:28989-28997
- Nouet S, Nahmias C (2000) Signal transduction from the angiotensin II AT₂ receptor. *Trends Endocrinol Metab* 11:1-6
- Nuyt AM, Lenkei Z, Palkovits M et al (1999) Ontogeny of angiotensin II type 2 receptor mRNA expression in fetal and neonatal rat brain. *J Comp Neurol* 407:193-206
- Oakley RH, Laporte SA, Holt JA et al (1999) Association of β -arrestin with G Protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. *J Biol Chem* 274:32248-32257
- Oakley RH, Laporte SA, Holt JA et al (2001) Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor- β -arrestin complexes after receptor endocytosis. *J Biol Chem* 276:19452-19460
- Ohlstein EH, Gellai M, Brooks DP et al (1992) The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin receptor antagonism. *J Pharmacol Exp Ther* 262:595-601
- Ohyama K, Yamano Y, Sano T et al (1995) Disulfide bridges in extracellular domains of angiotensin II receptor type 1A. *Regul Pept* 57:141-147
- Ohyama K, Yamano Y, Sano T et al (2002) Role of the conserved DRY motif on G protein activation of rat angiotensin II receptor type 1A. *Biochem Biophys Res Commun* 292:362-367
- Ojima M, Inada Y, Shibouta Y et al (1997) Candesartan (CV 11974) dissociates slowly from the angiotensin AT₁ receptor. *Eur J Pharmacol* 319:137-146
- Ohkubo N, Matsubara H, Nozawa Y et al (1997) Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. *Circulation* 96:3954-3962
- Olivares-Reyes JA, Smith RD, Hunyady L et al (2001) Agonist-induced signaling, desensitization and internalization of a phosphorylation-deficient AT_{1A} angiotensin receptor. *J Biol Chem* 276:37761-37768
- Oliverio MI, Best CF, Kim H-S et al (1997) Angiotensin II responses in AT_{1A} receptor-deficient mice: a role for AT_{1B} receptors in blood pressure regulation. *Am J Physiol* 272:F515-F520
- Oliverio MI, Madsen K, Best CF et al (1998 a) Renal growth and development in mice lacking AT_{1A} receptor for angiotensin II. *Am J Physiol* 274:F43-F50
- Oliverio MI, Kim H-S, Ito M et al (1998 b) Reduced growth, abnormal kidney structure and type 2 (AT₂) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT_{1A} and AT_{1B} receptors for angiotensin II. *Proc Natl Acad Sci USA* 95:15496-15501
- Oliverio MI, Coffman TM (2000) Angiotensin II receptor physiology using gene targeting. *News Physiol Sci* 15:171-175
- Oparil S, Williams D, Chrysant SG et al (2001) Comparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension. *J Clin Hypertens* 3:283-291
- Oppermann M, Freedman NJ, Alexander RW et al (1996 a) Phosphorylation of the type 1A angiotensin II receptor by G protein-coupled receptor kinases and protein kinase C. *J Biol Chem* 271:13266-13272

- Oppermann M, Diversé-Bierluissi H, Drazner MH et al (1996 b) Monoclonal antibodies reveal receptor specificity G-protein-coupled receptor kinases. *Proc Natl Acad Sci USA* 93:7649-7654
- Otsuka S, Sugano M, Makino N et al (1998) Interaction of mRNAs for angiotensin II type 1 and type 2 receptors to vascular remodelling in spontaneously hypertensive rats. *Hypertension* 32:467-472
- Ozono R, Wang Z-Q, Moore AF et al (1997) Expression of the subtype-2 angiotensin receptor protein in rat kidney. *Hypertension* 30:1238-1246
- Padia SH, Howell NL, Siragy HM et al (2006) Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor—blocked rat. *Hypertension* 47 (Pt 2):537-544
- Papademetriou V, Mammillot P, Redman R et al (2001) Prevention of atherosclerosis by specific AT1-receptor blockade with Candesartan cilexetil. *J Renin—Angiotensin-Aldosterone Syst* 2 (S 1) :S77-S80
- Paradis P, Dali-Youcef N, Paradis FW et al (2000) Overexpression of angiotensin II type 1 receptor in cardiomyocytes induces cardiac hypertrophy and remodelling. *Proc Natl Acad Sci USA* 97:931-936
- Parving HH, Lehnert H, Brochner-Mortensen J et al (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med* 345:870-878
- Patel MK, Betteridge LJ, Hughes AD et al (1996) Effect of angiotensin II on the expression of the early growth response gene *c-fos* and DNA synthesis in human vascular smooth muscle cells. *J Hypertens* 14:341-347
- Pfeffer MA, Swedberg K, Granger CB et al (2003) Effect of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet* 362:759-766
- Pham LTY, Ledingham JM, Cross MA et al (1994) A comparison of the effects of valsartan and enalapril on blood pressure and LV mass in New Zealand GH-rats. (abstract). 28th Annu Sci Meet ASCEPT, December 1997
- Philipp T, Letzel H, Arens H-J (1997) Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. *J Hum Hypertens* 11 (S2):S67-S68
- Philip MI, Schmidt-Otto KM (1999) The discovery of Renin 100 years ago. *News Physiol Sci* 14:271-274
- Pinheiro H, Moura D, Albino-Teixeira A et al (2002) A comparison of AT1 angiotensin antagonists on pre- and post-junctional angiotensin II receptor of the rat tail artery. *Naunyn Schmiedebergs Arch Pharmacol* 366:537-542
- Pitt B, Segal R, Martinez FA et al on behalf of ELITE Study Investigators (1997) Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). *Lancet* 349:747-752
- Pitt B, Poole-Wilson PA, Segal R et al (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - the Losartan Heart Failure Survival Study ELITE II. *Lancet* 355:1582-1587
- Pitt B (2002) Clinical trials with angiotensin receptor blockers in heart failure: what do we know and what will we can? *Am J Hypertens* 15:22S-27S
- Pollman MJ, Yamada T, Horiuchi M et al (1996) Vasoactive substances regulate vascular smooth muscle apoptosis. Countervailing influences of nitric oxide and angiotensin II. *Circ Res* 79:748-756
- Porsti I, Bara AT, Busse R et al (1994) Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. *Br J Pharmacol* 111:652-654
- Potts PD, Horiuchi J, Coleman MJ et al (2000) The cardiovascular effects of angiotensin-(1-7) in the rostral and caudal ventrolateral medulla of the rabbit. *Brain Res* 877:58-64
- Prasad A, Tupas-Habib T, Schenke WH et al (2000) Acute and chronic angiotensin-1 recep-

- tor antagonism reverses endothelial dysfunction in atherosclerosis. *Circulation* 101:2349-2354
- Pratt RE (1999) Angiotensin II and the control of cardiovascular structure. *J Am Soc Nephrol* 10:S120-S128
- Pulakat L, Cooper S, Knowle D et al (2005) Ligand-dependent formation between the angiotensin II receptor subtype AT2 and Na⁺/H⁺ exchanger NHE6 in mammalian cells. *Peptides* 26:863-873
- Qadri F, Wolf A, Waldmann T et al (1998) Sensitivity of hypothalamic paraventricular nucleus to C- and N-terminal angiotensin fragments - vasopressin release and drinking. *J Neuroendocrinol* 10:275-281
- Quian H, Pipolo L, Thomas WG (2001) Association of β -arrestin 1 with the type 1A angiotensin II receptor involves phosphorylation of the receptor carboxyl terminus and correlates with receptor internalization. *Mol Endocrinol* 15:1706-1719
- Raiden S, Nahmod K, Nahmod V et al (2002) Non peptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome. *J Pharmacol Exp Ther* 303:45-51
- Rajagopalan S, Kurz S, Munzel T et al (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. *J Clin Invest* 97:1916-1923
- Ran J, Hirano T, Adachi M (2005) Angiotensin II infusion increases hepatic triglyceride production via its type 2 receptor in rats. *J Hypertens* 23:1525-1530
- Razani B, Woodman SE, Lisanti MP (2002) Caveole: from cell biology to animal physiology. *Pharmacol Rev* 54:431-467
- Reagan LP, Yee DK, He PF et al (1996) Heterogeneity of angiotensin type 2 (AT2) receptors. *Adv Exp Med Biol* 396:199-208
- Reid JL (2005) Molecular-specific effects of angiotensin II antagonists: clinical relevance for treating hypertension? *J Renin-Angiotensin-Aldosterone Syst* 6:15-24
- Ren Y, Garvin JL, Carretero OA (2002) Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. *Hypertension* 39:799-802
- Reudelhuber TL (2006) A place in our hearts for the lowly angiotensin 1-7 peptide? *Hypertension* 47:811-815
- Reudelhuber TL (2005) The renin-angiotensin system: peptides and enzymes beyond Angiotensin II. *Curr Opin Nephrol Hypertens* 14:155-159
- Rice GI, Thomas DA, Grant PJ et al (2004) Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. *Biochem J* 383:45-51
- Robertson AL jr, Khairallah PA (1971) Angiotensin II: rapid localization in nuclei of smooth and cardiac muscle. *Science* 172:1138-1139
- Rowe BP, Saylor DL, Speth RC et al (1995) Angiotensin-(1-7) binding at angiotensin II receptors in the rat brain. *Regul Pept* 56:139-146
- Ruddy MC, Kostis JB (2005) Angiotensin II Receptor Antagonists. In: Oparil S, Weber MA (eds) *Hypertension*. Elsevier Saunders Phi., pp 705-724
- Saavedra JM, Viswanathan M, Shigematsu K (1993) Localization of angiotensin AT1 receptors in the rat heart conduction system. *Eur J Pharmacol* 235:301-303
- Saavedra JM (1999) Emerging features of brain angiotensin receptors. *Regul Pept* 85:31-45
- Saavedra JM, Ando H, Armando I et al (2005) Anti-stress and anti-anxiety effects of centrally acting angiotensin II AT1 receptor antagonists. *Regul Pept* 128:227-238
- Saavedra JM, Benicky J, Zhou J (2006) Angiotensin II: multitasking in the brain. *J Hypertens* 24 (S.I):S131-S137
- Sadoshima J (2002) Novel AT1 receptor-independent functions of losartan. *Circ Res* 90:754-756
- Sales VL, Sukhova GK, Lopez-Illasaca MA et al (2005) Angiotensin type 2 receptor is expressed in murine atherosclerotic lesions and modulates lesion evolution. *Circulation* 112:3328-3336

- Sano T, Ohyama K, Yamano Y et al (1997) A domain for 6 protein coupling in carboxyl-terminal tail of rat angiotensin II receptor type 1A. *J Biol Chem* 272:23631-23636
- Santos RAS, Campagnole-Santos MJ, Baracho NCV et al (1994) Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the action of angiotensin-(1-7) are mediated by specific angiotensin receptors. *Brain Res Bull* 35:293-298
- Santos RAS, Campagnole-Santos MJ, Andrade SP (2000) Angiotensin-(1-7): an update. *Regul Pept* 91:45-62
- Santos RAS, Simoes e Silva AC, Maric C et al (2003) Angiotensin-(1-7) is an endogenous ligand for G protein-coupled receptor Mas. *Proc Natl Acad Sci USA* 100:8258-8263
- Sardinia MF, Hanesworth JM, Krebs LT et al (1993) AT4 receptor binding characteristics: D-aminoacid- and glycine substituted peptides. *Peptides* 14:949-954
- Sasaki K, Yamaho Y, Bardhan S et al (1991) Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin type 1 receptor. *Nature* 351:230-233
- Sasaki K, Murohara T (2002) Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. *J Clin Invest* 109:603-611
- Sayeski PP, Showkat Ali M, Semeniuk DJ et al (1998) Angiotensin II signal transduction pathways. *Regul Pept* 78:19-29
- Schachter M (2000) ACE inhibitors, angiotensin receptor antagonists and bradykinin. *J Renin-Angiotensin-Aldosterone Syst* 1:27-29
- Schambye HT, Hjorth SA, Bergsma DJ et al (1994) Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors. *Proc Natl Acad Sci USA* 91:7046-7050
- Scheuer DA, Perrone MH (1993) Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. *Am J Physiol* 264:R917-R923
- Schiffirin EL, Park JB, Jntengan HD et al (2000) Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin antagonist losartan. *Circulation* 101:1653-1659
- Schiffirin EL, Hayoz D (2001) Role of AT1 Angiotensin Receptors in vascular Remodelling in Hypertension. In: Epstein M, Brunner HR (eds) *Angiotensin II Receptor Antagonists*. Hanley & Belfus Phil., pp 279-294
- Schiffirin EL (2002) Vascular and cardiac benefits of angiotensin receptor blockers. *Am J Med* 113:409-418
- Schiffirin EL, Touyz RM (2004) From bedside to bench to bedside: role of renin-angiotensin-aldosterone System in remodelling of resistance arteries in hypertension. *Am J Physiol* 287:H435-H446
- Schmaier AH (2003) The kallikrein-kinin and the renin-angiotensin systems have a multi-layered interaction. *Am J Physiol* 285:R1-R13
- Schmid C, Castrop H, Reitbauer J et al (1997) Dietary salt intake modulates angiotensin II type 1 receptor gene expression. *Hypertension* 29:923-929
- Schmid SL, McNiven MA, De Camilli P (1998) Dynamin and its partners: a progress report. *Curr Opin Cell Biol* 10:504-512
- Schneider MD, Lorell BH (2001) AT2, Judgment day. Which angiotensin receptor is the culprit in cardiac hypertrophy? *Circulation* 97:1952-1959
- Schnermann JB, Traynor T, Yang T et al (1997) Absence of tubuloglomerular feedback responses in AT1A receptor-deficient mice. *Am J Physiol* 273:F315-F320
- Schoenberger JA (1995) Losartan with hydrochlorothiazide in the treatment of hypertension. *J Hypertens* 13 (S.I):S43-S47
- Schrader J, Luders S, Kulschewski A et al (2003) The ACCESS study: evaluation of Acute candesartan cilexetil therapy in stroke survivors. *Stroke* 34:1699-1703
- Schrader J, Luders S, Kulschewski A et al (2005) Morbidity and mortality after Stroke, Eprosartan compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). *Stroke* 36:1218-1226
- Schuijijt MP, Ishida T, Ishida M et al (1999) No vasoactive role of the angiotensin II type 2 receptor in normotensive Wistar rats. *J Hypertens* 17:1879-1884

- Schulz R, Heusch G (2006) Angiotensin II type 1 receptors in cerebral ischemia-reperfusion: initiation of inflammation. *J Hypertens* 24 (S.1):S123-S129
- Schupp M, Janke J, Clasen R et al (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. *Circulation* 109:2054-2057
- Schupp M, Lee LD, Frost N et al (2006) Regulation of peroxisome proliferator-activated receptor γ activity by Losartan metabolites. *Hypertension* 47 (p 2):586-589
- Seachrist J, Laporte SA, Dale LB et al (2002) Rab5 association with the angiotensin II type 1A receptor promotes Rab5 GTP binding and vesicular fusion. *J Biol Chem* 277:679-685
- Sealey JE, Laragh JH (1995) The Renin-Angiotensin-Aldosterone System for normal Regulation of Blood Pressure and Sodium and Potassium Homeostasis. In: Laragh JH, Brenner BM (eds) *hypertension. Pathophysiology, Diagnosis and Management*. Raven Press New York, vol II, pp 1763-1796
- Sechi LA, Griffin CA, Grady EF et al (1992) Characterization of angiotensin II receptor subtypes in rat heart. *Circ Res* 71:1482-1489
- Senbonmatsu T, Ichihara S, Price E jr et al (2000) Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. *J Clin Invest* 106:R25-R29
- Servant G, Dudley DT, Escher E et al (1996) Analysis of the role of N-glycosylation in cell surface expression and binding properties of angiotensin II type-2 of rat pheochromocytoma cells. *Biochem J* 313:297-304
- Servant G, Laporte S, Leduc R et al (1997) Identification of angiotensin II-binding domains in the rat AT2 receptor with photolabile angiotensin analogs. *J Biol Chem* 272:8653-8659
- Seshiah PN, Weber DS, Rocic P et al (2002) Angiotensin II stimulation of NAD(P)H oxidase activity. Upstream mediators. *Circ Res* 91:406-413
- Sever P (2002) The SCOPE trial. *J Renin-Angiotensin-Aldosterone Syst* 3:61-62
- Shanmugam S, Llorens-Cortes C, Clauser E et al (1995) Expression of angiotensin II AT2 receptor mRNA during development of rat kidney and adrenal gland. *Am J Physiol* 268:F922-F930
- Sibley DR, Lefkowitz RJ (1985) Molecular mechanisms of receptor desensitization using the B-adrenergic receptor-coupled adenylate cyclase System as a model. *Nature* 317:124-129
- Sica DA (2002) The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors. *J Renin-Angiotensin-Aldosterone Syst* 3:66-71
- Sierra C, de la Sierra A (2005) Antihypertensive, cardiovascular and pleiotropic effects of angiotensin-receptor blockers. *Curr Opin Nephrol Hypertens* 14:435-441
- Silva LCS, Fontes MAP, Campagnole-Santos MJ et al (1993) Cardiovascular effects produced by microinjection of angiotensin-(1-7) in vasopressor and vasodepressor sites of the ventrolateral medulla. *Brain Res* 613:321-325
- Silvestre JS, Tamarat R et al (2002) Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. *Circ Res* 90:1072-1079
- Siragy HM, Carey RM (1996 a) The subtype 2 (AT2) angiotensin receptor regulates renal cyclic guanosine in conscious rats. *J Clin Invest* 97:1978-1982
- Siragy HM, Jaffa AA, Margolius HS et al (1996 b) Renin-angiotensin System modulates renal bradykinin production. *Am J Physiol* 271:R1090-R1095
- Siragy HM, Carey RM (1997) The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. *J Clin Invest* 100:264-269
- Siragy HM, Inagami T, Ichiki T et al (1999 a) Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype -2 (AT2) angiotensin receptor. *Proc Natl Acad Sci USA* 96:6506-6510
- Siragy HM, Senbonmatsu T, Ichiki T et al (1999 b) Increased renal vasodilator prostanoids prevent hypertension in mice lacking the angiotensin subtype 2 receptor. *J Clin Invest* 104:181-188
- Siragy HM, Carey RM (1999 c) Protective role of angiotensin AT2 receptor in a renal wrap hypertension model. *Hypertension* 33:1237-1242

- Siragy HM, de Gasparo M, Carey RM (2000) Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. *Hypertension* 35:1074-1077
- Siragy HM, Xue C, Abadir P et al (2005) Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation. *Hypertension* 45:133-137
- Skeggs LT, Lentz KE, Kahn JR (1956) The aminoacid sequence of hypertensin II. *J exp Med* 104:193-197
- Smith RD (1996) Atypical (Non-AT1, Non-AT2) angiotensin receptors. In: Raizada MK, Phillips MI, Sumners C (eds) *Recent Advances in Cellular and Molecular Aspects of Angiotensin Receptors*. Plenum Press New York, pp 237-245
- Smith RD, Hunyady L, Olivares-Reyes JA et al (1998) Agonist-induced phosphorylation of the angiotensin AT1A receptor is localized to a Serine/threonine-rich region of its cytoplasmic tail. *Mol Pharmacol* 54:935-941
- Song K, Zhuo J, Mendelsohn FAO (1991) Access of peripherally administered DuP 753 to rat brain angiotensin II receptors. *Br J Pharmacol* 104:771-772
- Stec DE, Sigmund CD (2001) Physiological insights from genetic manipulation of the renin-angiotensin System. *News Physiol Sci* 16:80-84
- Steckelings UM, Kaschina E, Unger T (2005) The AT2 receptor - A matter of love and hate. *Peptides* 26:1401-1409
- Stegbauer J, Vonend O, Habel S et al (2005) Angiotensin II modulates renal sympathetic neurotransmission through nitric oxide in AT2 receptor knockout mice. *J Hypertens* 23:1691-1698
- Stier CT jr, Adler LA, Levine S et al (1993) Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. *J Hypertens* 11 (S.3):S37-S42
- Stoll M, Steckelings UM, Bottari PM et al (1995) The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. *J Clin Invest* 95:651-657
- Stoll M, Unger T (2001) Angiotensin and its AT2 receptor: new insights into an old System. *Regul Pept* 99:175-182
- Strawn WB, Ferrario CM, Tallant EA (1999) Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. *Hypertension* 33:207-211
- Strawn WB, Chappell MC, Dean RH et al (2000 a) Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. *Circulation* 101:1585-1593
- Strawn WB, Dean RH, Ferrario CM (2000 b) Novel mechanisms linking angiotensin II and early atherogenesis. *J Renin-Angiotensin-Aldosterone Syst* 1:11-17
- Strehlow K, Nickenig G, Roeling J et al (1999) AT1 receptor regulation in salt-sensitive hypertension. *Am J Physiol* 277:H1701-1707
- Stroth U, Meffert S, Gallinat S et al (1998) Angiotensin II and NGF differentially influence microtubule proteins in PC12W cells: role of the AT2 receptor. *Brain Res Mol Brain Res* 53:187-195
- Sugaya T, Nishimatsu S, Tanimoto K et al (1995) Angiotensin II type 1A receptor-deficient mice with hypotension and hyperreninemia. *J Biol Chem* 270:18719-18722
- Sugino H, Ozono R, Kurisu S et al (2001) Apoptosis is not increased in myocardium overexpressing type 2 angiotensin receptors in transgenic mice. *Hypertension* 37:1394-1398
- Suzuki J, Iwai M, Nakagami H et al (2002) Role of angiotensin II-regulated apoptosis through distinct AT1 and AT2 receptors in neointima formation. *Circulation* 106:847-853
- Suzuki J, Kanazawa T, Iwai M et al (2004) Angiotensin II AT2 Receptors and Cardiac Function. In: De Mello WC (ed) *Renin Angiotensin System and the Heart*. J Wiley & Sons, Chichester, pp 85-99
- Swedberg K, Pfeffer M, Granger C et al (1999) For the Charm-programme investigators. Candesartan in heart failure- assessment of Reduction in Mortality (CHARM): rationale and design. *J Cardiac Failure* 5:276-282
- Tallant EA, Lu X, Weiss RB et al (1997) Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor. *Hypertension* 29:388-393
- Tallant EA, Clark MA (2003) Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). *Hypertension* 42:574-579

- Tang H, Guo DF, Porter JP et al (1998) Role of cytoplasmic tail of the type 1A angiotensin II receptor in agonist and phorbol ester-induced desensitization. *Circ Res* 82:523-531
- Tea B-S, Der Sarkissian S, Touyz RM et al (2000) Proapoptotic and growth-inhibitory role of angiotensin type 2 receptor in vascular smooth muscle cells of spontaneously hypertensive rats in vivo. *Hypertension* 35:1069-1073
- Tedesco MA, Ratti G, Mennella S et al (1999) Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life. *Am J Hypertens* 12:1130-1134
- Tenero D, Martin D, Ilson B et al (1998) Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food. *Biopharm Drug Dispos* 19:351-356
- Thomas WG, Thekkumkara TJ, Motel TJ et al (1995 a) Stable expression of a truncated AT1A receptor in CHO.K1 cells. *J Biol Chem* 270:207-213
- Thomas WG, Baker KM, Motel TJ et al (1995 b) Angiotensin II receptor endocytosis involves two distinct regions of the cytoplasmic tail. A role for residues on the hydrophobic phase of a putative amphipathic helix. *J Biol Chem* 270:22153-22159
- Thomas WG, Thekkumkara TJ, Baker KM (1996) Molecular mechanisms of angiotensin II (AT1A) receptor endocytosis. *Clin Exp Pharmacol Physiol* 23 (S.3):S74-S80
- Thomas WG, Motel TJ, Kule CE et al (1998) Phosphorylation of the angiotensin II (AT1A) receptor carboxyl terminus: A role in receptor endocytosis. *Mol Endocrinol* 12:1513-1524
- Thomas WG (1999) Regulation of angiotensin II type 1 (AT1) receptor function. *Regul Pept* 79:9-23
- Thomas WG (2000) Control of Angiotensin Action through Receptor Regulation. In: Husain A, Graham RM (eds) *Drugs, Enzymes and Receptors of the Renin-Angiotensin System*. Harwood Acad Publs, Amsterdam, pp 137-152
- Thomas WG (2005) Double trouble for type 1 angiotensin II receptors in atherosclerosis. *N Engl J Med* 352:506-508
- Thone-Reineke C, Steckelings U, Unger T (2006) Angiotensin receptor blockers and cerebral protection in stroke. *J Hypertens* 24 (S.I):S115-S121
- Tigerstedt R, Bergman PG (1898) Niere und kreislauf. *Scand Arch Physiol* 8:223-271
- Timmermans PBMWM, Wong PC, Chiu AT et al (1993) Angiotensin II receptors and Angiotensin II receptor antagonists. *Pharmacol Rev* 45:205-251
- Timmermans PBMWM, Wong PC, Chiu AT et al (1995) The preclinical basis of the therapeutic evolution of losartan. *J Hypertens* 13 (S.I):SI-SI 3
- Timmermans PBMWM, Smith R (1996) The diversified pharmacology of angiotensin -receptor blockade. *Blood Press* 5 (S.2):53-61
- Timmermans PBMWM (2001) Development of Nonpeptidic angiotensin II Receptor Antagonists. In: Epstein M, Brunner HR (eds) *Angiotensin II Receptor Antagonists*. Hanley & Belfus Phi., pp 89-103
- Tipnis SR, Hooper NM, Hyde R et al (2000) A human homolog of angiotensin-converting enzyme. *J Biol Chem* 275:33238-33243
- Toda N, Ayaziki K, Okamura T (1990) Modification by endogenous prostaglandins of angiotensin II-induced contraction in dogs and monkeys cerebral and mesenteric arteries. *J Pharmacol Expt Ther* 252:374-379
- Toney GM, Porter JP (1993) Functional roles of brain AT1 and AT2 receptors in the central angiotensin II pressor response in conscious young spontaneously hypertensive rats. *Brain Res Dev Brain Res* 71:193-199
- Touyz RM, He G, Deng LY et al (1999 a) Role of extracellular signal-regulated kinases in angiotensin II-stimulated contraction of smooth muscle cells from human resistance arteries. *Circulation* 99:392-399
- Touyz RM, Endemann D, He G et al (1999 b) Role of AT2 receptors in angiotensin II-stimulated contraction of small mesenteric arteries in young SHR. *Hypertension* 33:366-372
- Touyz RM, Schiffrin EL (2000) Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. *Pharmacol Rev* 52:1639-672

- Trenkwalder P (2006) The Study on Cognition and prognosis in the Elderly (SCOPE) - recent analyses. *J Hypertens* 24 (S.I):S107-S114
- Tronvik E, Stovner LJ, Schrader H et al (2006) Involvement of the renin-angiotensin System in migraine. *J Hypertens* 24 (S.I):S139-S143
- Tsuchida S, Matsusaka T, Chen X et al (1998) Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. *J Clin Invest* 101:755-760
- Tsutsumi K, Saavedra JM (1992) Heterogeneity of angiotensin AT₂ receptors in the rat brain. *Mol Pharmacol* 41:290-297
- Tsutsumi Y, Matsubara H, Ohkubo N et al (1998) Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis and cardiac fibroblasts are the major cell type for its expression. *Circ Res* 83:1035-1046
- Tsutsumi Y, Matsubara H, Masaki H et al (1999) Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilatation. *J Clin Invest* 104:925-935
- Tsuzuki S, Matoba T, Eguchi S et al (1996) Angiotensin II type-2 receptor inhibits cell proliferation and activates tyrosine phosphatase. *Hypertension* 28:916-918
- Turnbull F (2003) Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet* 362:1527-1535
- Unger T (1999) The angiotensin type 2 receptor: variations on an enigmatic theme. *J Hypertens* 17:1775-1786
- Unger T (2002) The role of the renin-angiotensin System in the development of cardiovascular disease. *Am J Cardiol* 89 (2A):3A-10
- Urata H, Nishimura H, Ganten D (1996) Chymase-dependent angiotensin II forming System in humans. *Am J Hypertens* 9:277-284
- Ushio-Fukai M, Griendling KK, Akers M et al (1998) Temporal dispersion of activation of phospholipase C- β 1 and γ isoforms by angiotensin II in vascular smooth muscle cells: Role of α q/11, α 2 and β γ G protein units. *J Biol Chem* 273:19772-19777
- Vallon V, Heyne N, Richter K et al (1998) 7-D-ALA -angiotensin-1-7 blocks renal actions of angiotensin-1-7 in the anesthetized rat. *J Cardiovasc Pharmacol* 32:164-167
- Vanderheyden PML, Fierens FLP, De Backer Jp et al (1999) Distinction between surmountable and insurmountable selective AT₁ receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT₁ receptors. *Br J Pharmacol* 126:1057-1065
- Vanderheyden PML, Fierens FLP, Vauquelin G (2000 a) Angiotensin II type 2 receptor antagonists. Why do some of them produce insurmountable inhibition? *Biochem Pharmacol* 60:1557-1563
- Vanderheyden PML, Fierens FLP, Backer JP et al (2000 b) Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors. *Biochem Pharmacol* 59:927-935
- Van Lier JJ, Van Heiningen PNM, Sunzen M (1997) Absorption, metabolism and excretion of C-Candesartan and C-candesartan cilexetil in healthy volunteers. *J Hum Hypertens* 11(S.2):S27-S28
- Vauquelin G, Fierens F, Vanderheyden P (2001) Distinction between Surmountable and Insurmountable Angiotensin II Receptor Antagonists. In: Epstein M, Brunner HR (eds) *Angiotensin II Receptor Antagonists*. Hanley & Belfus Phi., pp 105-118
- Vauquelin G, Michotte Y, Smolders I et al (2002) Cellular targets for angiotensin II fragments: pharmacological and molecular evidence. *J Renin-Angiotensin-Aldosterone Syst* 3:195-204
- Vauquelin G, Vanderheyden P (2004) AT₁ Receptor interactions. In: Unger T, Scholkens BA (eds) *Angiotensin*. Springer-Verlag Berlin Heidelberg, vol I, pp 297-315
- Verdecchia P, Porcellati C, Reboldi G et al (2001) Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. *Circulation* 104:2039-2044

- Vervoort VS, Beachem MA, Edwards PS et al (2002) AGTR2 mutations in X-linked mental retardation. *Science* 296:2401-2403
- Vibert G, Wheelton NM (2002) Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. *Circulation* 106:672-678
- Vickers C, Hales P, Kaushik V et al (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. *J Biol Chem* 277:14838-14843
- Viswanathan M, Tsutsumi K, Correa FM et al (1991) Changes in expression of angiotensin receptor subtypes in the rat aorta during development. *Biochem Biophys Res Commun* 179:1361-1367
- Viswanathan M, Selby DM, Ray PE (2000) Expression of renal and vascular angiotensin II receptor subtypes in children. *Pediatr Nephrol* 14:1030-1036
- Volpe M, Musumeci B, De Paolis P et al (2003) Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? *J Hypertens* 21:1429-1443
- Volpe M, Tocci G, Pagannone E (2006) Fewer mega-trials and more clinically oriented studies in hypertension research? The case of blocking the renin-angiotensin-aldosterone System. *J Am Soc Nephrol* 17:S36-S43
- Von Bohlen und Halbach O, Albrecht D (1998) Mapping of angiotensin AT1 receptors in the rat limbic system. *Regul Pept* 78:51-56
- Von Bohlen und Halbach O (2003) Angiotensin IV in the central nervous System. *Cell Tissue Res* 311:1-9
- Walters PE, Gaspari TA, Widdop RE (2005) Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. *Hypertension* 45:960-966
- Walther T, Simoes e Silva A, Maric C et al (2002) Cardiovascular active angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. *Circulation* 106:SII-S49
- Walther T, Menrad A, Orzechowski H-D et al (2003) Differential regulation of in vivo angiogenesis by angiotensin II receptors. *FASEB J* 17:2061-2067
- Wang C, Jayadev S, Escobedo JA (1995) Identification of a domain of the angiotensin II type 1 receptor determining Gq coupling by the use of receptor chimeras. *J Biol Chem* 270:16677-16682
- Wang ZQ, Moore AF, Ozono R et al (1998) Immunolocalization of subtype 2 angiotensin II (AT2) receptor protein in rat heart. *Hypertension* 32:78-83
- Wang JM, Tan J, Leenen FHH (2003 a) Central nervous system blockade by peripherally administration of AT1 receptor blockers. *J Cardiovasc Pharmacol* 41:593-599
- Wang C-H, Li S-H, Weisel RD et al (2003) C-Reactive Protein upregulates angiotensin type 1 receptors in vascular smooth muscle. *Circulation* 107:1783-1790
- Wang HW, Gallinat S, Li H-W et al (2004) Elevated blood pressure in normotensive rats produced by "knockdown" of the angiotensin type 2 receptor. *Exp Physiol* 89:313-322
- Warnholtz A, Nickenig G, Schulz E et al (1999) Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for the involvement of the renin-angiotensin system. *Circulation* 99:2027-2033
- Wassmann S, Nickenig G (2004) AT1 Receptor Regulation. In: Unger T, Scholkens BA (eds) *Angiotensin*. Springer-Verlag Berlin Heidelberg, vol 1, pp 317-333
- Wassmann S, Nickenig G (2006) Pathophysiological regulation of the AT1-receptor and implications for vascular disease. *J Hypertens* 24 (S1):S15-S21
- Watanabe T, Suzuki J, Yamawaki H et al (2005) Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells. Angiotensin II type 1 receptor-independent effects of EXP3179. *Circulation* 112:1798-1805
- Wachtele K, Lehto M, Gerdtts E et al (2005) Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. *J Am Coll Cardiol* 45:712-719
- Weber DS, Lombard JH (2001) Angiotensin II AT1 receptors preserve vasodilator reactivity in skeletal muscle resistance arteries. *Am J Physiol* 280:H2196-H2202

- Weber MA (2003) Angiotensin II blockers and cardiovascular outcomes: what does the future hold? *J Renin-Angiotensin-Aldosterone Syst* 4:62-73
- Weinberg MS, Weinberg AJ, Zappe DH (2000) Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors. *J Renin-Angiotensin-Aldosterone Syst* 1:217-233
- Werner N, Nickenig G (2003) AT1 receptors in atherosclerosis: biological effects including growth, angiogenesis and apoptosis. *Eur Heart J* 5 (S.A):A9-A13
- Wharton J, Morgan K, Rutherford RAD et al (1998) Differential distribution of angiotensin AT2 receptors in the normal and failing human heart. *J Pharmacol Exp Ther* 284:323-336
- Whitebread SE, Mele M, Kamber B et al (1989) Preliminary biochemical characterization of two angiotensin II receptor subtypes. *Biochem Biophys Res Commun* 165:196-203
- Widdop RE, Gardiner SM, Kemp PA et al (1992) Inhibition of the hemodynamic effects of angiotensin II in conscious rats by AT2 receptor antagonists given after the AT1 receptor antagonist EWP3074. *Br J Pharmacol* 107:873-880
- Widdop RE, Gardiner SM, Kemp PA et al (1993) Central administration of PD13319 or EXP3174 inhibits effect of angiotensin II. *Am J Physiol* 264:H117-H125
- Widdop RE, Sampey DB, Jarrott B (1999) Cardiovascular effects of angiotensin-(1-7) in conscious spontaneously hypertensive rats. *Hypertension* 34:964-968
- Widdop RE, Matrougui K, Levy BL et al (2002) AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. *Hypertension* 40:516-520
- Widdop RE, Jones ES, Hannan RE et al (2003) Angiotensin AT2 receptors: cardiovascular hope or hype? *Br J Pharmacol* 140:809-824
- Wienen W, Entzeroth M, Van Meel JCA et al (2000) A review on telmisartan: a novel, long-acting angiotensin II receptor antagonist. *Cardiovasc Drug Rev* 18:127-156
- Williams B (2004) VALUE and supremacy of blood pressure control for cardiovascular protection. *J Hypertens* 22:1435-1437
- Wong PC, Price WA, Chiu AT et al (1990 a) Non peptide angiotensin receptor antagonists. IX. Antihypertensive activity in rats of DuP753, an orally active antihypertensive agent. *J Pharmacol Exp Ther* 252:726-732
- Wong PC, Price WA, Chiu AT et al (1990 b) Hypotensive action of DuP753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists: X. *Hypertension* 15:459-468
- Wong PC, Price WA, Chiu AT et al (1990 c) Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174, an active metabolite of DuP753 - an orally active antihypertensive agent. *J Pharmacol Exp Ther* 255:726-732
- Wong PC, Timmermans PBMWM (1991) Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DupP753. *J Pharmacol Exp Ther* 258:49-57
- Wong PC, Hajj-ali AF (1994) Functional Correlates of Angiotensin Receptor Stimulation. In: Timmermans PBMWM, Wexler RR (eds) *Medicinal Chemistry of the Renin -Angiotensin System*. Elsevier Amsterdam, pp 313-346
- Wong SK, Li W, Moore MJ et al (2004) A 193-aminoacid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. *J Biol Chem* 279:3197-3201
- Wright JW, Krebs LT, Stobb JW et al (1995) The angiotensin IV system: functional implications. *Front Neuroendocrinol* 16:23-52
- Wright JW, Stubbley L, Pederson ES et al (1999) Contribution of the brain angiotensin IV-AT4 receptor subtype System to spatial learning. *J Neurosci* 19:3952-3961
- Wruck C, Stoll M, Unger T (2004) AT2 Functions and Target Genes. In: Unger T, Scholkens BA (eds): *Angiotensin*. Springer-Verlag Heidelberg, Newyork, vol. I, pp 449-475
- Wruck CJ, Funke-Kaiser H, Pufe T et al (2005) Regulation of transport of the angiotensin AT2 receptor by a novel membrane-associated Golgi protein. *Arterioscler Thromb Vasc Biol* 25:57-64

- Wu L, Iwai M, Nakagami H et al (2001) Role of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. *Circulation* 104:2716-2721
- Xiao C Li, Widdop RS (2004) AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR. *Br J Pharmacol* 142:821-830
- Xiong H, Marshall KC (1994) Angiotensin II depresses glutamate depolarization and excitatory postsynaptic potentials in locus coeruleus through angiotensin II subtype 2 receptors. *Neuroscience* 62:163-175
- Xoriuchi M, Hamai M, Cui TX et al (1999) Cross talk between angiotensin II type 1 and type 2 receptors; cellular mechanisms of angiotensin type 2 receptor-mediated cellgrowth inhibition. *Hypertens Res Clin Exp* 22:67-74
- Xu Y, Kumar D, Dick JRB et al (2002) AT1 and AT2 receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts. *Am J Physiol* 282:H1206-H1215
- Yagil Y, Yagil C (2003) Hypothesis: ACE2 modulated blood pressure in the mammalian organism. *Hypertension* 41:871-873
- Yamada T, Horiuchi M, Dzau VJ (1996) Angiotensin type 2 receptor mediates programmed cell death. *Proc Natl Acad Sci USA* 93:156-160
- Yamano Y, Ohyama K, Kikyo M et al (1995) Mutagenesis and the molecular modeling of the rat angiotensin II receptor (AT1). *J Biol Chem* 270:14024-14030
- Yan X, Price RL, Nakayama L et al (2003) Vascular specific expression of angiotensin II type 2 receptors causes dilated cardiomyopathy and heart failure in transgenic rats. *Am J Physiol* 285:H2179-H2187
- Yang Z, Bove CM, French BA et al (2002) Angiotensin II type 2 receptor expression preserves left ventricular function after myocardial infarction. *Circulation* 106:106-111
- Yee D, Heering J, Krichavsky M et al (1998) Role of the aminoterminal in ligand binding domains of the rat AT2 receptor with photolabile angiotensin analogs. *Brain Res Mol Brain Res* 57:325-329
- Yoshida H, Kakuchi J, Guo D et al (1992) Analysis of the evolution of angiotensin II type 1 receptor gene in mammals (mouse, rat, bovine and human). *Biophys Res Commun* 186:1042-1049
- Yoshida M, Naito Y, Urano T et al (2002) L158-809 and (D-Ala (7)-angiotensin I/II (1-7) decrease PAI-1 release from human umbilical vein endothelial cells. *Res* 105:531-536
- You D, Loufrani L, Baron C et al (2005) High blood pressure reduction reverses angiotensin II type 2 receptor-mediated vasoconstriction into vasodilation in spontaneously hypertensive rats. *Circulation* 111:1006-1011
- Yu SP, Yeh CH, Sensi SL et al (1997) Mediation of neuronal apoptosis by enhancement of outward potassium current. *Science* 278:114-117
- Yusuf S, Pfeffer MA, Swedberg K et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. *Lancet* 362:777-781
- Zanchetti A (2001) Morbidity and Mortality Trials with Angiotensin Receptor Antagonists in Hypertensive Patients. In: Epstein M, Brunner HR (eds) *Angiotensin II Receptor Antagonists*. Hanley & Belfus Phi., pp 351-360
- Zhang J, Pratt RE (1996) The AT2 receptor selectively associates with G α 2 G α 3 in the rat fetus. *J Biol Chem* 271:15026-15033
- Zhang JH, Hanesworth JM, Sardinia M et al (1999 a) Structural analysis of angiotensin IV receptor (AT4) from selected bovine tissues. *J Pharmacol Exp Ther* 289:1075-1083
- Zhang J, Barak LS, Anborgh PH et al (1999b) Cellular trafficking of G protein-coupled receptor/ β -arrestin endocytic complexes. *J Biol Chem* 274:10999-11006
- Zhang M, Zhao X, Chen HC et al (2000) Activation of the AT1 angiotensin receptor is dependent on adjacent apolar residues in the carboxyl terminus of the third cytoplasmic loop. *J Biol Chem* 275:15782-15788
- Zhu M, Gelband CH, Moore JM et al (1998) Angiotensin II type 2 receptor stimulation of

- neuronal delayed-rectifier potassium current involves phospholipase A2 and arachidonic acid. *J Neurosci* 18:679-686
- Zhuo J, Alcorn D, Harris PJ et al (1997) Angiotensin II receptor subtypes in the kidney: Distribution and functions. *Nephrology* 1:511-525
- Zhuo J, Moeller I, Jenkins T et al (1998) Mapping angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptors. *J Hypertens* 16:2027-2037
- Zisman LS, Keller RS, Weaver B et al (2003) Increased angiotensin-(1-7)-forming activity in failing human heart ventricles. Evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. *Circulation* 108:1707-1712
- Zisman LS (2004) ACE2: Its Role in the Counter-regulatory Response to Heart Failure. In: De Mello WC (ed) *Renin Angiotensin System and the Heart*. J. Wiley & Sons, Chichester UK, pp 119-135

Sigle a singola lettera ed a tre lettere per gli aminoacidi

Aminoacido	Una lettera	Tre lettere
Alanina	A	Ala
Arginina	R	Arg
Asparagina	N	Asn
Acido aspartico	D	Asp
Cisteina	C	Cys
Glutamina	Q	Gln
Acido glutamico	E	Glu
Glicina	G	Gly
Istidina	H	His
Isoleucina	I	Ile
Leucina	L	Leu
Lisina	K	Lys
Metionina	M	Met
Fenilalanina	F	Phe
Prolina	P	Pro
Serina	S	Ser
Treonina	T	Thr
Triptofano	W	Trp/Try
Tirosina	Y	Tyr
Valina	V	Val
Non specificato o non noto	X	Xaa

Indice analitico

- ACCESS 145
ACE2 e antagonisti AT1 (AT1RA) 124-125
ACE2 e recettori AT2 67 segg.
ACE2 e SARS 69
Ang- (1-7) e recettori AT2 69, 125
Ang 1-9 67
Antagonisti competitivi e non competitivi 112
Antagonisti sormontabili ed insormontabili 112
Associazione AT1RA/ACEI 138
AT1P 76
ATRAP 37
- Beta arrestine 34 segg.
- CAKUT 72
CALM 145
Caveole 36-37
CHARM 141
- Dimerizzazione 86
Dinamina 35
DIRECT 122
- ELITE 1 e 2 140 segg.
EXP 3179 119
- “Flessibilità” dei recettori del SRA 101
- IDNT 143
- IRAP 5
IRMA2 143
- LIFE 132 segg.
- “Magic tait” 14
MARVAL 143
Mas Oncogene e recettori AT1 88
Mas Oncogene e recettore Ang- (1-7) 7
MOSES 146
- ONTARGET 139
OPTIMAAL 142
- PPAR- γ 119
Proteina ATBP 50 58
- Rab 5a 36
Rab 7 36
Recettore AT1 e apoptosi 85
Recettore AT2 e cascata vasodilatatrice 65
Recettori AT2 e inibizione ACE 66
RENAAL 143
ROS 49
- SCOPE 135
- VAL-HEFT 141
VALIANT 142
VALUE 136

Finito di stampare nel mese di marzo 2007